WHO Drug Information Vol. 25, No. 3, 2011                                                 Recommended INN: List 66



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 66
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in Cumulative List
No. 13, 2009 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 66
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans
la Liste récapitulative No. 13, 2009 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 66
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran
reunidas en Cumulative List No. 13, 2009 (disponible sólo en CD-ROM).


                                                                                                                 295
Recommended INN: List 66                                              WHO Drug Information Vol. 25, No. 3, 2011




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 abediterolum
 abediterol                                5-[(1R)-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-
                                           1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one

 abéditérol                                5-[(1R)-2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-
                                           1-hydroxyéthyl]-8-hydroxyquinoléin-2(1H)-one

 abediterol                                5-[(1R)-2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil]-
                                           8-hidroxiquinolin-2(1H)-ona

                                           C25H30F2N2O4


                                                        H OH
                                                                H
                                                                N
                                                                                      O
                                                                                          F   F
                                            HO
                                                  HN

                                                       O



 adomiparinum natricum
 adomiparin sodium                         sodium salt of a low molecular mass heparin obtained by enzymatic
                                           depolymerization of heparin from porcine intestinal mucosa; the
                                           majority of the components have a 4-deoxy-α-L-threo-hex-
                                           4-enopyranuronic acid or it 4-hydroxy saturated derivative at the
                                           non-reducing end and a 2-amino-2-deoxy-D-glucopyranose
                                           derivative structure at the reducing end of their chain; the relative
                                           average molecular mass range is 5,500 to 9,000 daltons and a
                                           polydispersity of less than 1.5; the degree of sulfation is about 2.6
                                           per disaccharidic unit

 adomiparine sodique                       sel sodique d'héparine de faible masse moléculaire obtenu par
                                           dépolymérisation enzymatique d'héparine de muqueuse intestinale
                                           de porc ; la majorité des composants possèdent une structure acide
                                           4-déoxy-α-L-thréo-hex-4-énopyranuronique ou son dérivé saturé
                                           4-hydroxylé à l'extrémité non réductrice de leur chaîne et une
                                           structure 2-amino-2-désoxy-D-glucopyranose à l'extrémité réductrice
                                           de leur chaîne ; la masse moléculaire relative est en moyenne
                                           comprise entre 5500 et 9000 et son indice de polymolécularité est
                                           inférieure à 1,5 ; le degré de sulfatation est d'environ 2,6 par unité
                                           disaccharide.




296
WHO Drug Information Vol. 25, No. 3, 2011                                                   Recommended INN: List 66




 adomiparina sódica                         sal sódica de heparina de baja masa molecular obtenida por
                                            despolimerización enzimática de heparina de mucosa intestinal de
                                            cerdo; la mayoría de cuyos componentes tienen un ácido 4-desoxi-
                                            α-L-treo-hex-4-enopiranurónico o su derivado saturado 4-hidroxilado
                                            en el extremo no reductor de la cadena y una 2-amino-2-desoxi-
                                            D-glucopiranosa en el reductor; la masa molecular relativa media
                                            está comprendida entre 5500 y 9000 y su índice de polidispersión es
                                            inférior a 1,5; el grado de sulfatación es aproximadamente 2,6 par
                                            unidad de disacárido.




 aganepagum
 aganepag                                   5-{3-[(2S)-1-{4-[(1S)-1-hydroxyhexyl]phenyl}-5-oxopyrrolidin-
                                            2-yl]propyl}thiophene-2-carboxylic acid

 aganépag                                   acide 5-{3-[(2S)-1-{4-[(1S)-1-hydroxyhexyl]phényl}-5-oxopyrrolidin-
                                            2-yl]propyl}thiophène-2-carboxylique

 aganepag                                   ácido 5-{3-[(2S)-1-{4-[(1S)-1-hidroxihexil]fenil}-5-oxopirrolidin-
                                            2-il]propil}tiofeno-2-carboxílico

                                            C24H31NO4S

                                                 H
                                                                  S        CO2H

                                                 N

                                             O                                    CH3

                                                              H   OH



 alisertibum
 alisertib                                  4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-
                                            d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid

 alisertib                                  acide 4-{[9-chloro-7-(2-fluoro-6-méthoxyphényl)-5H-pyrimido[5,4-
                                            d][2]benzazépin-2-yl]amino}-2-méthoxybenzoïque

 alisertib                                  ácido 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5H-pirimido[5,4-
                                            d][2]benzazepin-2-il]amino}-2-metoxibenzoico

                                            C27H20ClFN4O4

                                                     Cl
                                              H3C
                                                     O                     H
                                                                   N       N

                                                                       N
                                                          N                              CO2H
                                                     F                            OCH3




                                                                                                                  297
Recommended INN: List 66                              WHO Drug Information Vol. 25, No. 3, 2011


 alvelestatum
 alvelestat                N-{[5-(methanesulfonyl)pyridin-2-yl]methyl}-6-methyl-5-(1-methyl-
                           1H-pyrazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-
                           1,2-dihydropyridine-3-carboxamide

 alvélestat                N-{[5-(méthanesulfonyl)pyridin-2-yl]méthyl}-6-méthyl-5-(1-méthyl-
                           1H-pyrazol-5-yl)-2-oxo-1-[3-(trifluorométhyl)phényl]-
                           1,2-dihydropyridine-3-carboxamide

 alvelestat                N-{[5-(metanosulfonil)piridin-2-il]metil}-6-metil-5-(1-metil-1H-pirazol-
                           5-il)-2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridina-3-carboxamida

                           C25H22F3N5O4S

                              F3C


                                                             O O
                              H3C         N   O               S
                                                                CH3
                                                  H
                                                  N
                                                         N

                            N N               O
                                    CH3

 amatuximabum #
 amatuximab                immunoglobulin G1-kappa, anti-[Homo sapiens MSLN (mesothelin,
                           pre-pro-megakaryocyte-potentiating factor, megakaryocyte-
                           potentiating factor, MPF, CAK1)], chimeric monoclonal antibody;
                           gamma1 heavy chain (1-449) [Mus musculus VH (IGHV1-37*01 -
                           (IGHD)-IGHJ2*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                           449)], (222-213')-disulfide with kappa light chain (1'-213') [Mus
                           musculus V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -
                           Homo sapiens IGKC*01 (107'-213')]; (228-228'':231-231'')-
                           bisdisulfide dimer

 amatuximab                immunoglobuline G1-kappa, anti-[Homo sapiens MSLN
                           (mésothéline, facteur de potentialisation du pré-pro-mégacaryocyte,
                           facteur de potentialisation des mégacaryocytes, MPF, CAK1)],
                           anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-449) [Mus musculus VH (IGHV1-37*01 -
                           (IGHD)-IGHJ2*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                           449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213')
                           [Mus musculus V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106')
                           -Homo sapiens IGKC*01 (107'-213')]; dimère (228-228'':231-231'')-
                           bisdisulfure

 amatuximab                inmunoglobulina G1-kappa, anti-[MSLN de Homo sapiens
                           (mesotelina, factor de potenciación del pre-pro-megacariocito, factor
                           de potenciación de megacariocitos, MPF, CAK1)], anticuerpo
                           monoclonal quimérico;
                           cadena pesada gamma1 (1-449) [Mus musculus VH (IGHV1-37*01 -
                           (IGHD)-IGHJ2*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                           449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [Mus
                           musculus V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -
                           Homo sapiens IGKC*01 (107'-213')]; dímero (228-228'':231-231'')-
                           bisdisulfuro




298
WHO Drug Information Vol. 25, No. 3, 2011                                                           Recommended INN: List 66




                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLQQSGPE LEKPGASVKI SCKASGYSFT                  GYTMNWVKQS       HGKSLEWIGL        50
                                            ITPYNGASSY NQKFRGKATL TVDKSSSTAY                  MDLLSLTSED       SAVYFCARGG       100
                                            YDGRGFDYWG SGTPVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                            ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                            YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIELTQSPAI MSASPGEKVT MTCSASSSVS                  YMHWYQQKSG       TSPKRWIYDT 50
                                            SKLASGVPGR FSGSGSGNSY SLTISSVEAE                  DDATYYCQQW       SKHPLTFGSG 100
                                            TKVEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                                            NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                                            SSPVTKSFNR GEC                                                                213

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        146-202       263-323  369-427
                                                      22''-96'' 146''-202'' 263''-323'' 369''-427''
                                            Intra-L 23'-87' 133'-193'
                                                     23'''-87''' 133'''-193'''
                                            Inter-H-L 222-213' 222''-213'''
                                            Inter-H-H 228-228'' 231-231''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            299, 299''



 arbaclofenum
 arbaclofen                                 (3R)-4-amino-3-(4-chlorophenyl)butanoic acid

 arbaclofène                                (-)-acide (3R)-4-amino-3-(4-chlorophényl)butanoïque

 arbaclofeno                                ácido (3R)-4-amino-3-(4-clorofenil)butanoico

                                            C10H12ClNO2

                                                   H2N         H
                                                                     CO2H


                                            Cl



 asfotasum alfa #
 asfotase alfa                              tissue-nonspecific alkaline phosphatase-IgG1 fusion protein;
                                            human tissue-nonspecific isozyme alkaline phosphatase (AP-TNAP,
                                            EC=3.1.3.1) fusion protein with leucyl-lysyl-human immunoglobulin
                                            G1 Fc region {(6-15)-H-CH2-CH3 of IGHG1*03} fusion protein with
                                            aspartyl-isoleucyl-deca(aspartic acid), dimer (493-493':496-496')-
                                            bisdisulfide

 asfotase alfa                              protéine de fusion phosphatase alcaline humaine isozyme tissulaire
                                            non-spécifique-IgG1;
                                            phosphatase alcaline humaine isozyme tissulaire non-spécifique
                                            (AP-TNAP, EC=3.1.3.1) protéine de fusion avec la leucyl-lysyl-région
                                            Fc {(6-15)-H-CH2-CH3 de l'IGHG1*03} de l'immunoglobuline G1
                                            humaine protéine de fusion avec l'aspartyl-isoleucyl-déca(acide
                                            aspartique), (493-493':496-496')-bisdisulfure du dimère




                                                                                                                                      299
Recommended INN: List 66                                      WHO Drug Information Vol. 25, No. 3, 2011




 asfotasa alfa             proteína de fusión fosfatasa alcalina humana isozima tisular
                           inespecífica-IgG1;
                           fosfatasa alcalina humana isozima tisular inespecífica (AP-TNAP,
                           EC=3.1.3.1) proteína de fusión con la leucil-lisil-región Fc {(6-15)-H-
                           CH2-CH3 del IGHG1*03} de la inmunoglobulinea G1 humana
                           proteína de fusión con aspartil-isoleucil-deca(acide aspártico), (493-
                           493':496-496')-bisdisulfuro del diméro

                           C7108H11008N1968O2206S56 (peptide)

                           Monomer / Monomère / Monómero
                           LVPEKEKDPK YWRDQAQETL KYALELQKLN                       TNVAKNVIMF        LGDGMGVSTV         50
                           TAARILKGQL HHNPGEETRL EMDKFPFVAL                       SKTYNTNAQV        PDSAGTATAY         100
                           LCGVKANEGT VGVSAATERS RCNTTQGNEV                       TSILRWAKDA        GKSVGIVTTT         150
                           RVNHATPSAA YAHSADRDWY SDNEMPPEAL                       SQGCKDIAYQ        LMHNIRDIDV         200
                           IMGGGRKYMY PKNKTDVEYE SDEKARGTRL                       DGLDLVDTWK        SFKPRYKHSH         250
                           FIWNRTELLT LDPHNVDYLL GLFEPGDMQY                       ELNRNNVTDP        SLSEMVVVAI         300
                           QILRKNPKGF FLLVEGGRID HGHHEGKAKQ                       ALHEAVEMDR        AIGQAGSLTS         350
                           SEDTLTVVTA DHSHVFTFGG YTPRGNSIFG                       LAPMLSDTDK        KPFTAILYGN         400
                           GPGYKVVGGE RENVSMVDYA HNNYQAQSAV                       PLRHETHGGE        DVAVFSKGPM         450
                           AHLLHGVHEQ NYVPHVMAYA ACIGANLGHC                       APASSLKDKT        HTCPPCPAPE         500
                           LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV                       VDVSHEDPEV        KFNWYVDGVE         550
                           VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW                       LNGKEYKCKV        SNKALPAPIE         600
                           KTISKAKGQP REPQVYTLPP SREEMTKNQV                       SLTCLVKGFY        PSDIAVEWES         650
                           NGQPENNYKT TPPVLDSDGS FFLYSKLTVD                       KSRWQQGNVF        SCSVMHEALH         700
                           NHYTQKSLSL SPGKDIDDDD DDDDDD                                                                726

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           122-184 122'-184' 472-480 472'-480' 528-588
                           528'-588' 634-692 634'-692' 493-493' 496-496'

                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-123 Asn-123' Asn-213 Asn-213' Asn-254 Asn-254'
                           Asn-286 Asn-286' Asn-413 Asn-413' Asn-564 Asn-564'




 atinumabum #
 atinumab                  immunoglobulin G4-kappa, anti-[Homo sapiens RTN4 (reticulon 4,
                           neurite outgrowth inhibitor, NOGO), isoform A], Homo sapiens
                           monoclonal antibody;
                           gamma4 heavy chain (1-441) [Homo sapiens VH (IGHV3-7*01
                           (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01
                           (115-441)], (128-214')-disulfide with kappa light chain (1'-214')
                           [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01
                           R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (220-220'':223-
                           223'')-bisdisulfide dimer

 atinumab                  immunoglobuline G4-kappa, anti-[Homo sapiens RTN4 (réticulon 4,
                           inhibiteur de la croissance des neurites, NOGO), isoforme A], Homo
                           sapiens anticorps monoclonal;chaîne lourde gamma4 (1-441) [Homo
                           sapiens VH (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S)
                           [8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfure avec la
                           chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-
                           11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01
                           (108'-214')]; dimère (220-220'':223-223'')-bisdisulfure

 atinumab                  inmunoglobulina G4-kappa, anti-[ RTN4 de Homo sapiens (reticulón
                           4, inhibidor del crecimiento de las neuritas, NOGO), isoforma A],
                           anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma4 (1-441) [VH de Homo sapiens (IGHV3-7*01
                           (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01
                           (115-441)], (128-214')-disulfuro con la cadena ligera kappa (1'-214')
                           [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01
                           R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (220-
                           220'':223-223'')-bisdisulfuro



300
WHO Drug Information Vol. 25, No. 3, 2011                                                            Recommended INN: List 66


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LVQPGGSLRL SCAASGFTFS                    NYWMSWVRQA     PGKGLEWVAT        50
                                            IKQDGSQKNY VDSVKGRFTI SRDNAKNSLY                    LRLNSLRAED     TAVYYCATEL       100
                                            FDLWGRGSLV TVSSASTKGP SVFPLAPCSR                    STSESTAALG     CLVKDYFPEP       150
                                            VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS                    SVVTVPSSSL     GTKTYTCNVD       200
                                            HKPSNTKVDK RVESKYGPPC PSCPAPEFLG                    GPSVFLFPPK     PKDTLMISRT       250
                                            PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN                    AKTKPREEQF     NSTYRVVSVL       300
                                            TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI                    SKAKGQPREP     QVYTLPPSQE       350
                                            EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ                    PENNYKTTPP     VLDSDGSFFL       400
                                            YSRLTVDKSR WQEGNVFSCS VMHEALHNHY                    TQKSLSLSLG     K                441

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPAT LSLSPGERAT LSCRASQSVS                    SYLAWYQQKP     GQAPRLLIYD 50
                                            ASNRATGIPA RFSGSGSGTD FTLTISSLEP                    EDFAVYYCQQ     RSNWPITFGQ 100
                                            GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                    SVVCLLNNFY     PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                    LSKADYEKHK     VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                               214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        141-197       255-315  361-419
                                                      22''-96'' 141''-197'' 255''-315'' 361''-419''
                                            Intra-L 23'-88'      134'-194'
                                                     23'''-88''' 134'''-194'''
                                            Inter-H-L 128-214' 128''-214'''
                                            Inter-H-H 220-220'' 223-223''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            291, 291''


 atopaxarum
 atopaxar                                   2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydro-2H-isoindol-2-yl)-
                                            1-[3-tert-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethan-1-one

 atopaxar                                   2-(5,6-diéthoxy-7-fluoro-1-imino-1,3-dihydro-2H-isoindol-2-yl)-
                                            1-[3-tert-butyl-4-méthoxy-5-(morpholin-4-yl)phényl]éthanone

 atopaxar                                   2-(5,6-dietoxi-7-fluoro-1-imino-1,3-dihidro-2H-isoindol-2-il)-1-[3-terc-
                                            butil-4-metoxi-5-(morfolin-4-il)fenil]etan-1-ona

                                            C29H38FN3O5

                                                               F         NH                H3C
                                                                                                     CH3
                                            H3 C       O
                                                                                                     CH3
                                                                          N
                                            H3 C       O                                             OCH3
                                                                               O
                                                                                                 N

                                                                                                     O

 bisegliptinum
 bisegliptin                                ethyl 4-({2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-
                                            2-oxoethyl}amino)bicyclo[2.2.2]octane-1-carboxylate

 biségliptine                               4-({2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-
                                            2-oxoéthyl}amino)bicyclo[2.2.2]octane-1-carboxylate d'éthyle

 bisegliptina                               4-({2-[(2S,4S)-2-ciano-4-fluoropirrolidin-1-il]-
                                            2-oxoetil}amino)biciclo[2.2.2]octano-1-carboxilato de etilo

                                            C18H26FN3O3

                                                                                   O       H CN
                                                                           H
                                                                           N
                                                                                       N
                                            H3C        O
                                                                                                 H
                                                           O                                F



                                                                                                                                        301
Recommended INN: List 66                                 WHO Drug Information Vol. 25, No. 3, 2011


 burixaforum
 burixafor                 (2-{4-[6-amino-2-({[(1r,4r)-4-({[3-
                           (cyclohexylamino)propyl]amino}methyl)cyclohexyl]methyl}amino)
                           pyrimidin-4-yl]piperazin-1-yl}ethyl)phosphonic acid

 burixafor                 acide (2-{4-[6-amino-2-({[(1r,4r)-4-({[3-
                           (cyclohexylamino)propyl]amino}méthyl)cyclohexyl]méthyl}amino)
                           pyrimidin-4-yl]pipérazin-1-yl}éthyl)phosphonique

 burixafor                 ácido (2-{4-[6-amino-2-({[(1r,4r)-4-({[3-
                           (ciclohexilamino)propil]amino}metil)ciclohexil]metil}amino)pirimidin-
                           4-il]piperazin-1-il}etil)fosfónico

                           C27H51N8O3P

                                                                                                O
                                                                                                P    OH
                                    N                N                                   N
                                    H                H                 H                            OH
                                                                       N       N     N

                                                                           N

                                                                               NH2

 cadazolidum
 cadazolid                 1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxymethyl)-
                           2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-
                           4-oxo-1,4-dihydroquinolin-3-carboxylic acid

 cadazolid                 acide 1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-
                           (hydroxyméthyl)-2-oxo-1,3-oxazolidin-3-yl]phénoxy}méthyl)-
                           4-hydroxypipéridin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

 cadazolid                 ácido 1-ciclopropil-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hidroximetil)-
                           2-oxo-1,3-oxazolidin-3-il]fenoxi}metil)-4-hidroxipiperidin-1-il]-4-oxo-
                           1,4-dihidroquinolin-3-carboxílico

                           C29H29F2N3O8

                                     O       O
                                H
                           HO
                                         N
                                                             OH
                                                         O
                                                 F                 N                 N


                                                                   F                     CO2H
                                                                                     O
 carlumabum #
 carlumab                  immunoglobulin G1-kappa, anti-[Homo sapiens CCL2 (chemokine
                           (C-C motif) ligand 2, C-C motif chemokine 2, monocyte
                           chemoattractant protein-1, MCP-1, monocyte chemotactic and
                           activating factor, MCAF, small inducible cytokine A2, SCYA2,
                           HC11)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV1-69*01
                           (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)),
                           (222-216')-disulfide with kappa light chain (1'-216') [Homo sapiens
                           V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -
                           IGKC*01 (110'-216')]; (228-228'':231-231'')-bisdisulfide dimer


302
WHO Drug Information Vol. 25, No. 3, 2011                                                            Recommended INN: List 66


 carlumab                                   immunoglobuline G1-kappa, anti-[Homo sapiens CCL2 (chimiokine
                                            (C-C motif) ligand 2, C-C motif chimiokine 2, protéine 1
                                            chimioattractante du monocyte, MCP-1, facteur activateur et
                                            chimiotactique du monocyte, MCAF, SCYA2, HC11)], Homo sapiens
                                            anticorps monoclonal;
                                            chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV1-69*01
                                            (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)),
                                            (222-216')-disulfure avec la chaîne légère kappa (1'-216') [Homo
                                            sapiens V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10]
                                            (1'-109') -IGKC*01 (110'-216')]; dimère (228-228'':231-231'')-
                                            bisdisulfure

 carlumab                                   inmunoglobulina G1-kappa, anti-[Homo sapiens CCL2 (quimiokina
                                            (C-C motif) ligando 2, C-C motif quimiokina 2, proteìna 1
                                            quimiotàctica de monocito, MCP-1, factor activador y quimiotàctico
                                            de monocito, MCAF, SCYA2, HC11)], anticuerpo monoclonal de
                                            Homo sapiens;
                                            cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV1-69*01
                                            (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)),
                                            (222-216')-disulfuro con la cadena ligera kappa (1'-216') [Homo
                                            sapiens V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10]
                                            (1'-109') -IGKC*01 (110'-216')]; dìmero (228-228'':231-231'')-
                                            bisdisulfuro


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVQSGAE VKKPGSSVKV SCKASGGTFS                  SYGISWVRQA       PGQGLEWMGG        50
                                            IIPIFGTANY AQKFQGRVTI TADESTSTAY                  MELSSLRSED       TAVYYCARYD       100
                                            GIYGELDFWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                            ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                            YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  DAYLAWYQQK       PGQAPRLLIY 50
                                            DASSRATGVP ARFSGSGSGT DFTLTISSLE                  PEDFAVYYCH       QYIQLHSFTF 100
                                            GQGTKVEIKR TVAAPSVFIF PPSDEQLKSG                  TASVVCLLNN       FYPREAKVQW 150
                                            KVDNALQSGN SQESVTEQDS KDSTYSLSST                  LTLSKADYEK       HKVYACEVTH 200
                                            QGLSSPVTKS FNRGEC                                                             216

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        146-202       263-323  369-427
                                                      22''-96'' 146''-202'' 263''-323'' 369''-427''
                                            Intra-L 23'-89'      136'-196'
                                                     23'''-89''' 136'''-196'''
                                            Inter-H-L 222-216' 222''-216'''
                                            Inter-H-H 228-228'' 231-231''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            299, 299''


 cenisertibum
 cenisertib                                 (1S,2S,3R,4R)-3-{[5-fluoro-2-({3-methyl-4-(4-methylpiperazin-
                                            1-yl)phenyl}amino)pyrimidin-4-yl]amino}bicyclo[2.2.1]hept-5-ene-
                                            2-carboxamide

 cénisertib                                 (1S,2S,3R,4R)-3-[(5-fluoro-2-{[3-méthyl-4-(4-méthylpipérazin-
                                            1-yl)phényl]amino}pyrimidin-4-yl)amino]bicyclo[2.2.1]hept-5-ène-
                                            2-carboxamide

 cenisertib                                 (1S,2S,3R,4R)-3-{[5-fluoro-2-({3-metil-4-(4-metilpiperazin-
                                            1-il)fenil}amino)pirimidin-4-il]amino}biciclo[2.2.1]hept-5-eno-
                                            2-carboxamida




                                                                                                                                        303
Recommended INN: List 66                                             WHO Drug Information Vol. 25, No. 3, 2011


                           C24H30FN7O
                                                                                       CH3
                                                                         CH3       N
                                        F                                      N
                                                         N
                                  O
                                      H HN          N            N
                                                H                H
                           H2N
                              H                     H




 crolibulinum
 crolibulin                (4R)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene-
                           3-carbonitrile

 crolibuline               (4R)-2,7,8-triamino-4-(3-bromo-4,5-diméthoxyphényl)-4H-chromène-
                           3-carbonitrile

 crolibulina               (4R)-2,7,8-triamino-4-(3-bromo-4,5-dimetoxifenil)-4H-cromeno-
                           3-carbonitrilo

                           C18H17BrN4O3

                                                NH2
                                                             NH2


                                                             O
                                            H
                           H3CO
                                                                 NH2
                                                        CN
                           H3CO
                                       Br



 darexabanum
 darexaban                 N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-
                           1,4-diazepan-1-yl)benzamide

 darexaban                 N-[2-hydroxy-6-(4-méthoxybenzamido)phényl]-4-(4-méthyl-
                           1,4-diazépan-1-yl)benzamide

 darexabán                 N-[2-hidroxi-6-(4-metoxibenzamido)fenil]-4-(4-metil-1,4-diazepan-
                           1-il)benzamida

                           C27H30N4O4

                                                                 HO
                                                             O
                                                                                        OCH3
                                                                     N
                                                                     H
                                                                         HN
                                       N
                                                                               O
                                 N
                           H3C




304
WHO Drug Information Vol. 25, No. 3, 2011                                                Recommended INN: List 66


 delamanidum
 delamanid                                  (2R)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-
                                            1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole

 délamanid                                  (2R)-2-méthyl-6-nitro-2-[(4-{4-[4-(trifluorométhoxy)phénoxy]pipéridin-
                                            1-yl}phénoxy)méthyl]-2,3-dihydroimidazo[2,1-b]oxazole

 delamanid                                  (2R)-2-metil-6-nitro-2-[(4-{4-[4-(trifluorometoxi)fenoxi]piperidin-
                                            1-il}fenoxi)metil]-2,3-dihidroimidazo[2,1-b][1,3]oxazol

                                            C25H25F3N4O6

                                                                                          O

                                                                                 N
                                                                                                      OCF3
                                                      N        O
                                            O2N                          O
                                                           N           CH3


 edivoxetinum
 edivoxetine                                (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-
                                            4-yl)ethan-1-ol

 édivoxétine                                (1R)-2-(5-fluoro-2-méthoxyphényl)-1-[(2S)-morpholin-2-yl]-1-(oxan-
                                            4-yl)éthan-1-ol

 edivoxetina                                (1R)-2-(5-fluoro-2-metoxifenil)-1-[(2S)-morfolin-2-il]-1-(oxan-4-il)etan-
                                            1-ol

                                            C18H26FNO4

                                               F                   O

                                                      HO
                                                               H


                                               OCH3        O           NH


 efinaconazolum
 efinaconazole                              (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-
                                            1-(1H-1,2,4-triazin-1-yl)butan-2-ol

 éfinaconazole                              (2R,3R)-2-(2,4-difluorophényl)-3-(4-méthylènepipéridin-1-yl)-
                                            1-(1H-1,2,4-triazol-1-yl)butan-2-ol

 efinaconazol                               (2R,3R)-2-(2,4-difluorofenil)-3-(4-metilenopiperidin-1-il)-
                                            1-(1H-1,2,4-triazin-1-il)butan-2-ol

                                            C18H22F2N4O

                                                                             F


                                            H2C                F
                                                               HO
                                                           N

                                                           H CH3 N
                                                                            N
                                                                       N




                                                                                                                   305
Recommended INN: List 66                             WHO Drug Information Vol. 25, No. 3, 2011




 egaptivonum pegolum
 egaptivon pegol           a pegylated aptamer which binds von Willebrand factor;
                           5'-O-{[6-(carboxyamino)hexyl]hydroxyphosphoryl}-2'-O-
                           methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
                           methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxyguanylyl-
                           (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-O-
                           methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                           methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
                           methylcytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                           methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
                           methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                           methylcytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-O-methyl-P-
                           thioguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-
                           2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-
                           (3'→5')-thymidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                           methylcytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-O-methyluridylyl-
                           (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-O-
                           methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxycytidylyl-
                           (3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-
                           O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→3')-thymidine,
                           carbamate ester with monomethyl ether of polyethylene gycol (20
                           kDa)

 egaptivon pégol           aptamère pégylé qui se lie au facteur de von Willebrand;
                           ester carbamique entre l'éther monométhylique du
                           polyéthylèneglycol (macrogol 20 kDa) et le 5'-O-{[6-
                           (carboxyamino)hexyl]hydroxyphosphoryl}-2'-O-méthylguanylyl-
                           (3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-
                           O-méthyluridylyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-2'-
                           désoxycytidylyl-(3'→5')-2'-désoxyadénylyl-(3'→5')-2'-O-
                           méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                           méthylguanylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                           méthylcytidylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                           méthylguanylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                           méthylcytidylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-O-méthyl-P-
                           thioguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-
                           2'-désoxycytidylyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-2'-
                           désoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-O-méthylguanylyl-
                           (3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-désoxycytidylyl-
                           (3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-
                           désoxycytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-
                           méthylcytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                           méthylcytidylyl-(3'→3')-thymidine




306
WHO Drug Information Vol. 25, No. 3, 2011                                                      Recommended INN: List 66


 egaptivón pegol                            aptámero pegilado que se une al factor de von Willebrand;
                                            éster carbámico entre el éter monometílico del polietilenglicol
                                            (macrogol 20 kDa) y el 5'-O-{[6-(carboxiamino)hexil]hidroxifosforil}-
                                            2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilguanilil-
                                            (3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-
                                            desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-O-metilguanilil-
                                            (3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-
                                            metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-
                                            2'-O-metiluridilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilguanilil-
                                            (3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-
                                            desoxicitidilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-timidilil-(3'→5')-
                                            2'-O-metilguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-
                                            (3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-2'-O-metilguanilil-
                                            (3'→5')-2'-O-metilcitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-O-
                                            metiluridilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-
                                            O-metilguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxicitidilil-
                                            (3'→5')-2'-O-mtiladenilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-
                                            metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→3')-timidina

                                            C413H546N144O275P40S (C2H4O)n

                                                                  H
                                                                  N      O             CH3
                                                                                   O
                                                                                       n
                                                                O
                                            (3'-5')(   p Gm Cm Gm Um dG              dC dA      Gm Um Gm Cm Cm

                                            Um Cm Gm Gm Cm dC Gm sp dT Gm dC dG dG dT Gm

                                            Gm Cm dC Um dC dC Gm Um dC Am Cm Gm Cm3' 3'dT)



 elobixibatum
 elobixibat                                 [(2R)-2-(2-{[3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-
                                                                      6
                                            2,3,4,5-tetrahydro-1H-1λ ,5-benzothiazepin-8-yl]oxy}acetamido)-
                                            2-phenylacetamido]acetic acid

 élobixibat                                 acide [(2R)-2-(2-{[3,3-dibutyl-7-(méthylsulfanyl)-1,1-dioxo-5-phényl-
                                                                      6
                                            2,3,4,5-tétrahydro-1H-1λ ,5-benzothiazépin-8-yl]oxy}acétamido)-
                                            2-phénylacétamido]acétique

 elobixibat                                 ácido [(2R)-2-(2-{[3,3-dibutil-5-fenil-7-(metilsulfanil)-1,1-dioxo-
                                                                     6
                                            2,3,4,5-tetrahidro-1H-1λ ,5-benzotiazepin-8-il]oxi}acetamido)-
                                            2-fenilacetamido]acético

                                            C36H45N3O7S2


                                                       CH3
                                                                               CH3
                                                                  N            S
                                                                                                 O
                                            H3C                                            H
                                                                                           N
                                                                 S             O                     N    CO2H
                                                                                                     H
                                                                O O                    O   H




                                                                                                                         307
Recommended INN: List 66                                WHO Drug Information Vol. 25, No. 3, 2011




 elsiglutidum
 elsiglutide               [2-glycine(A>G),3-glutamic acid(D>E),8-serine(D>S),10-
                           leucine(M>L),11-serine(N>S),16-alanine(N>A),24-alanine(N>A),28-
                           alanine(Q>A)]human glucagon-like peptide 2 (GLP-2) fusion protein
                           with hexalysinamide

 elsiglutide               [2-glycine(A>G),3-acide glutamique(D>E),8-sérine(D>S),10-
                           leucine(M>L),11-sérine(N>S),16-alanine(N>A),24-alanine(N>A),28-
                           alanine(Q>A)]peptide 2 semblable au glucagon humain (GLP-2)
                           protéine de fusion avec l'hexalysinamide

 elsiglutida               [2-glicina(A>G),3-acide glutámico(D>E), 8-serina(D>S),10-
                           leucina(M>L),11-serina(N>S),16-alanina(N>A),24-alanina(N>A),28-
                           alanina(Q>A)]péptido 2 similar al glucagón humano(GLP-2) proteína
                           de fusión con hexalisinamida

                           C196H323N53O56

                           HGEGSFSSEL             STILDALAAR    DFIAWLIATK          ITDKKKKKK   39

                           Modified residue / Résidu modifié / Residuo modificado
                           K   lysinamide




 empagliflozinum
 empagliflozin             (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-
                           3-yl]oxy}phenyl)methyl]phenyl}-D-glucitol

 empagliflozine            (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-
                           3-yl]oxy]}phényl)méthyl]phényl}-D-glucitol

 empagliflozina            (1S)-1,5-anhidro-1-C-{4-cloro-3-[(4-{[(3S)-oxolan-
                           3-il]oxi}fenil)metil]fenil}-D-glucitol

                           C23H27ClO7

                                 H
                                 O            O




                                         Cl

                           HO

                                     O
                                OH
                           HO
                                     OH




308
WHO Drug Information Vol. 25, No. 3, 2011                                                             Recommended INN: List 66


 enavatuzumabum #
 enavatuzumab                               immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF12A (tumor
                                            necrosis factor receptor superfamily member 12A, fibroblast growth
                                            factor (FGF)-inducible 14 kDa protein, Fn14, TNF-like weak inducer
                                            of apoptosis (Tweak) receptor, Tweak receptor, TweakR, CD266],
                                            humanized monoclonal antibody;
                                            gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                                            IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10]
                                            (1-119) -Homo sapiens IGHG1*01 CH3 D12>E (358), L14>M (360)
                                            (120-449)], (222-218')-disulfide with kappa light chain (1'-218')
                                            [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (84.80%) -
                                            IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')];
                                            (228-228":231-231")-bisdisulfide dimer

 énavatuzumab                               immunoglobuline G1-kappa, anti-[Homo sapiens TNFRSF12A
                                            (membre 12A de la superfamille des récepteurs du facteur de
                                            nécrose tumorale, protéine de 14 kDa induite par le facteur de
                                            croissance du fibroblaste (FGF), Fn14, TNF-like faible inducteur
                                            d'apoptose (Tweak), récepteur de Tweak, CD266], anticorps
                                            monoclonal humanisé;
                                            chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                                            IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10]
                                            (1-119) -Homo sapiens IGHG1*01 CH3 D12>E (358), L14>M (360)
                                            (120-449)], (222-218')-disulfure avec la chaîne légère kappa (1'-218')
                                            [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (84.80%) -
                                            IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')];
                                            dimère (228-228":231-231")-bisdisulfure

 enavatuzumab                               inmunoglobulina G1-kappa, anti-[TNFRSF12A de Homo sapiens
                                            (miembro 12A de la superfamilia de receptores del factor de
                                            necrosis tumoral, proteína de 14 kDa inducida por el factor de
                                            crecimiento de fibroblastos (FGF), Fn14, TNF-like débil inductor de
                                            apoptosis (Tweak), receptor de Tweak, CD266], anticuerpo
                                            monoclonal humanizado;
                                            cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens
                                            IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10]
                                            (1-119) -Homo sapiens IGHG1*01 CH3 D12>E (358), L14>M (360)
                                            (120-449)], (222-218')-disulfuro con la cadena ligera kappa (1'-218')
                                            [V-KAPPA humanizada (Homo sapiens IGKV1-39*01 (84.80%) -
                                            IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')];
                                            dímero (228-228":231-231")-bisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  SYWMSWVRQA       PGKGLEWVAE        50
                                            IRLKSDNYAT HYAESVKGRF TISRDDSKNS                  LYLQMNSLRA       EDTAVYYCTG       100
                                            YYADAMDYWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                            ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                            YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIQMTQSPSS LSASVGDRVT ITCRASQSVS                  TSSYSYMHWY       QQKPGKAPKL 50
                                            LIKYASNLES GVPSRFSGSG SGTDFTLTIS                  SLQPEDFATY       YCQHSWEIPY 100
                                            TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                                            QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                                            THQGLSSPVT KSFNRGEC                                                           218

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-98 146-202              263-323  369-427
                                                     22''-98'' 146''-202'' 263''-323'' 369''-427''
                                            Intra-L 23'-92' 138'-198'
                                                     23'''-92''' 138'''-198'''
                                            Inter-H-L 222-218' 222''-218'''
                                            Inter-H-H 228-228'' 231-231''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            299, 299''


                                                                                                                                          309
Recommended INN: List 66                                     WHO Drug Information Vol. 25, No. 3, 2011


 enokizumabum #
 enokizumab                immunoglobulin G1-kappa, anti-[Homo sapiens IL9 (interleukin 9,
                           IL-9, T cell growth factor p40)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-452) [humanized VH (Homo sapiens
                           IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo
                           sapiens IGHG1*03 (123-452)], (225-214')-disulfide with kappa light
                           chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-39*01
                           (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                           214')]; (231-231":234-234")-bisdisulfide dimer

 énokizumab                immunoglobuline G1-kappa, anti-[Homo sapiens IL9 (interleukine 9,
                           IL-9, facteur de croissance p40 des cellules T)], anticorps
                           monoclonal humanisé;
                           chaîne lourde gamma1 (1-452) [VH humanisé (Homo sapiens
                           IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo
                           sapiens IGHG1*03 (123-452)], (225-214')-disulfure avec la chaîne
                           légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-
                           39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dimère (231-231":234-234")-bisdisulfure

 enokizumab                inmunoglobulina G1-kappa, anti-[IL9 de Homo sapiens (interleukina
                           9, IL-9, factor de crecimiento p40 de células T)], anticuerpo
                           monoclonal humanizado;
                           cadena pesada gamma1 (1-452) [VH humanizada (Homo sapiens
                           IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo
                           sapiens IGHG1*03 (123-452)], (225-214')-disulfuro con la cadena
                           ligera kappa (1'-214') [V-KAPPA humanizada (Homo sapiens IGKV1-
                           39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGSSVKV SCKASGGTFS                  YYWIEWVRQA       PGQGLEWMGE        50
                           ILPGSGTTNP NEKFKGRVTI TADESTSTAY                  MELSSLRSED       TAVYYCARAD       100
                           YYGSDYVKFD YWGQGTLVTV SSASTKGPSV                  FPLAPSSKST       SGGTAALGCL       150
                           VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT       200
                           QTYICNVNHK PSNTKVDKRV EPKSCDKTHT                  CPPCPAPELL       GGPSVFLFPP       250
                           KPKDTLMISR TPEVTCVVVD VSHEDPEVKF                  NWYVDGVEVH       NAKTKPREEQ       300
                           YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                  KALPAPIEKT       ISKAKGQPRE       350
                           PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS                  DIAVEWESNG       QPENNYKTTP       400
                           PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC                  SVMHEALHNH       YTQKSLSLSP       450
                           GK                                                                                  452

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCKASQHVI                  THVTWYQQKP       GKAPKLLIYG 50
                           TSYSYSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       FYEYPLTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H    22-96       149-205      266-326        372-430
                                    22''-96''     149''-205''     266''-326''    372''-430''
                           Intra-L    23'-88'     134'-194'
                                      23'''-88'''   134'''-194'''
                           Inter-H-L      225-214'      225''-214'''
                           Inter-H-H     231-231''      234-234''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           302, 302''



 erteberelum
 erteberel                 (3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-
                           hexahydrocyclopenta[c]chromen-8-ol

 ertébérel                 (3aS,4R,9bR)-4(4-hydroxyphényl)-1,2,3,3a,4,9b-
                           hexahydrocyclopenta[c][1]chromén-8-ol




310
WHO Drug Information Vol. 25, No. 3, 2011                                              Recommended INN: List 66


 erteberel                                  (3aS,4R,9bR)-4-(4-hidroxifenil)-1,2,3,3a,4,9b-
                                            hexahidrociclopenta[c]cromen-8-ol

                                            C18H18O3

                                                         HH
                                                                       OH
                                                 H
                                                          O


                                            HO




 etrolizumabum #
 etrolizumab                                immunoglobulin G1-kappa, anti-[Homo sapiens integrins
                                            ITGA4_ITGB7 (integrin alpha4 (CD49d)_beta7, integrin α4β7,
                                            lymphocyte Peyer's patch adhesion molecule 1, LPAM-1) and
                                            ITGAE_ITGB7 (integrin alphaE (CD103, alphaIEL)_beta7, integrin
                                            αEβ7, HML-1], humanized monoclonal antibody;
                                            gamma1 heavy chain (1-446) [humanized VH (Homo sapiens
                                            IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -Homo
                                            sapiens IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-
                                            446)], (220-214')-disulfide with kappa light chain (1'-214') [humanized
                                            V-KAPPA (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9]
                                            (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (226-226":229-229")-
                                            bisdisulfide dimer

 étrolizumab                                immunoglobuline G1-kappa, anti-[Homo sapiens intégrines
                                            ITGA4_ITGB7 (intégrine alpha4 (CD49d)_bêta7, intégrine α4β7,
                                            récepteur d'adressage spécifique des plaques de Peyer, LPAM-1) et
                                            ITGAE_ITGB7 (intégrine alphaE (CD103, alphaIEL)_bêta7, intégrine
                                            αEβ7, HML1)], anticorps monoclonal humanisé;
                                            chaîne lourde gamma1 (1-446) [VH humanisé (Homo sapiens
                                            IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -Homo
                                            sapiens IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-
                                            446)], (220-214')-disulfure avec la chaîne légère kappa (1'-214')
                                            [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (85.30%) -
                                            IGKJ1*01) [6.4.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                            dimère (226-226":229-229")-bisdisulfure

 etrolizumab                                immunoglobuline G1-kappa, anti-[integrinas ITGA4_ITGB7 de Homo
                                            sapiens (integrina alfa4 (CD49d)_beta7, integrina α4β7, molécula de
                                            adhesión específica de linfocitos de las placas de Peyer, LPAM-1) e
                                            ITGAE_ITGB7 (integrina alfaE (CD103, alfaIEL)_beta7, integrina
                                            αEβ7, HML1)], anticuerpo monoclonal humanizado;
                                            cadena pesada gamma1 (1-446) [VH humanizada (Homo sapiens
                                            IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -Homo
                                            sapiens IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-
                                            446)], (220-214')-disulfuro con la cadena ligera kappa (1'-214')
                                            [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (85.30%) -
                                            IGKJ1*01) [6.4.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                            dímero (226-226":229-229")-bisdisulfuro




                                                                                                                 311
Recommended INN: List 66                                      WHO Drug Information Vol. 25, No. 3, 2011


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFFIT                   NNYWGWVRQA      PGKGLEWVGY        50
                           ISYSGSTSYN PSLKSRFTIS RDTSKNTFYL                   QMNSLRAEDT      AVYYCARTGS       100
                           SGYFDFWGQG TLVTVSSAST KGPSVFPLAP                   SSKSTSGGTA      ALGCLVKDYF       150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                   SLSSVVTVPS      SSLGTQTYIC       200
                           NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                   APELLGGPSV      FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                   GVEVHNAKTK      PREEQYNSTY       300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                   PIEKTISKAK      GQPREPQVYT       350
                           LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                   WESNGQPENN      YKTTPPVLDS       400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                   ALHNHYTQKS      LSLSPG           446

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASESVD                   DLLHWYQQKP      GKAPKLLIKY 50
                           ASQSISGVPS RFSGSGSGTD FTLTISSLQP                   EDFATYYCQQ      GNSLPNTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                   SVVCLLNNFY      PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                   LSKADYEKHK      VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214


                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H    22-95        144-200         261-321     367-425
                                    22''-95''   144''-200''    261''-321''   367''-425''
                           Intra-L    23'-88'    134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L      220-214'    220''-214'''
                           Inter-H-H      226-226''    229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           297, 297''

                    18
 florbenazinum ( F)
               18                                    18
 florbenazine ( F)         (2R,3R,11bR)-9-(3-[ F]fluoropropoxy)-10-methoxy-
                           3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-
                           a]isoquinolin-2-ol
               18                                    18
 florbénazine ( F)         (2R,3R,11bR)-9-(3-[ F]fluoropropoxy)-10-méthoxy-
                           3-(2-méthylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-
                           a]isoquinoléin-2-ol
               18                                    18
 florbenazina ( F)         (2R,3R,11bR)-9-(3-[ F]fluoropropoxi)-3-(2-metilpropil)-10-metoxi-
                           1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol
                                    18
                           C21H32 FNO3

                                                                H OH
                                                                                  CH3
                                                          H               H
                                         H3CO                                 CH3
                                                                  N

                           [18F]              O

 forigerimodum
                            3,140
 forigerimod               O   -phosphono(human U1 small nuclear ribonucleoprotein 70 kDa
                           (snRNP70))-(131-151)-peptide
                            3,140
 forigérimod               O    -phosphono(petite ribonucléoprotéine nucléaire U1 humaine de
                           70 kDa (snRNP70))-(131-151)-peptide
                            3,140
 forigerimod               O    -fosfono(pequeña ribonucleoproteína nuclear U1 humana de 70
                           kDa (snRNP70))-(131-151)-péptido




312
WHO Drug Information Vol. 25, No. 3, 2011                                                              Recommended INN: List 66


                                            C117H181N34O32PS

                                            RIHMVYSKRS GKPRGYAFIE Y                                                21

                                            Modified residues / Résidus modifiés / Residuos modificados
                                                                                   OH
                                                      S                                 OH
                                                      10                       O P
                                               O3,10-phosphono
                                                                                      O         H
                                                (phosphoserine)
                                                                                          N      C
                                                                                          H
                                                                                                 O
 fulranumabum #
 fulranumab                                 immunoglobulin G2-kappa, anti-[Homo sapiens NGF (nerve growth
                                            factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)],
                                            Homo sapiens monoclonal antibody;
                                            gamma2 heavy chain (1-449) [Homo sapiens VH (IGHV3-48*02
                                            (92.90%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -IGHG2*01 (124-449)],
                                            (137-214')-disulfide with kappa light chain (1'-214') [Homo sapiens
                                            V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -
                                            IGKC*01 (108'-214')]; (225-225'':226-226':229-229'':232-232''')-
                                            tetrakisdisulfide dimer

 fulranumab                                 immunoglobuline G2-kappa, anti-[Homo sapiens NGF (facteur de
                                            croissance du nerf, facteur de croissance du nerf polypeptide bêta,
                                            NGFB, bêta-NGF)], Homo sapiens anticorps monoclonal;
                                            chaîne lourde gamma2 (1-449) [Homo sapiens VH (IGHV3-48*02
                                            (92.90%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -IGHG2*01 (124-449)],
                                            (137-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo
                                            sapiens V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-
                                            107') -IGKC*01 (108'-214')]; dimère (225-225'':226-226':229-
                                            229'':232-232''')-tétrakisdisulfure

 fulranumab                                 inmunoglobulina G2-kappa, anti-[NGF de Homo sapiens (factor de
                                            crecimiento de nervios, factor de crecimiento de nervios polipétido
                                            beta, NGFB, beta-NGF)], anticuerpo monoclonal de Homo sapiens;
                                            cadena pesada gamma2 (1-449) [Homo sapiens VH (IGHV3-48*02
                                            (92.90%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -IGHG2*01 (124-449)],
                                            (137-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo
                                            sapiens V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-
                                            107') -IGKC*01 (108'-214')]; dímero (225-225'':226-226':229-
                                            229'':232-232''')-tetrakisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LVQPGGSLRL SCAASGFTLR                  SYSMNWVRQA       PGKGLEWVSY        50
                                            ISRSSHTIFY ADSVKGRFTI SRDNAKNSLY                  LQMDSLRDED       TAMYYCARVY       100
                                            SSGWHVSDYF DYWGQGILVT VSSASTKGPS                  VFPLAPCSRS       TSESTAALGC       150
                                            LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSNFG       200
                                            TQTYTCNVDH KPSNTKVDKT VERKCCVECP                  PCPAPPVAGP       SVFLFPPKPK       250
                                            DTLMISRTPE VTCVVVDVSH EDPEVQFNWY                  VDGVEVHNAK       TKPREEQFNS       300
                                            TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL                  PAPIEKTISK       TKGQPREPQV       350
                                            YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPML       400
                                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                            Light chain / Chaîne légère / Cadena ligera
                                            AIQLTQSPSS LSASVGDRVT ITCRASQGIS                  SALAWYQQKP       GKAPKLLIYD 50
                                            ASSLESGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       FNSYPLTFGG 100
                                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                               214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        150-206 263-323        369-427
                                                     22''-96'' 150''-206'' 263''-323'' 369''-427''
                                            Intra-L 23'-88'      134'-194'
                                                     23'''-88''' 134'''-194'''
                                            Inter-H-L 137-214' 137''-214'''
                                            Inter-H-H 225-225'' 226-226'' 229-229'' 232-232''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            299, 299''


                                                                                                                                              313
Recommended INN: List 66                             WHO Drug Information Vol. 25, No. 3, 2011




 gaxilosum
 gaxilose                  4-O-β-D-galactopyranosyl-D-xylose

 gaxilose                  4-O-β-D-galactopyranosyl-D-xylose

 gaxilosa                  4-O-β-D-galactopiranosil-D-xilosa

                           C11H20O10

                                                O
                           HO
                                           OH        OH
                           HO        O O
                                OH              OH


                                     OH




 gevokizumabum #
 gevokizumab               immunoglobulin G2-kappa, anti-[Homo sapiens IL1B (interleukin 1
                           beta, 1L1F2, IL-1B)], humanized monoclonal antibody;
                           gamma2 heavy chain (1-445) [humanized VH (Homo sapiens
                           IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -Homo
                           sapiens IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfide
                           with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens
                           IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9] (1'-107') -
                           Homo sapiens IGKC*01 (108'-214')]; (222-222":223-223":226-
                           226":229-229")-tetrakisdisulfide dimer

 gévokizumab               immunoglobuline G2-kappa, anti-[Homo sapiens IL1B (interleukine 1
                           bêta, 1L1F2, IL-1B)], anticorps monoclonal humanisé;
                           chaîne lourde gamma2 (1-445) [VH humanisé (Homo sapiens
                           IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -Homo
                           sapiens IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfure
                           avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo
                           sapiens IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (222-
                           222":223-223":226-226":229-229")-tétrakisdisulfure

 gevokizumab               inmunoglobulina G2-kappa, anti-[IL1B de Homo sapiens
                           (interleukina 1 beta, 1L1F2, IL-1B)], anticuerpo monoclonal
                           humanizado;
                           cadena pesada gamma2 (1-445) [VH humanizada (Homo sapiens
                           IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -Homo
                           sapiens IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfuro
                           con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo
                           sapiens IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (222-
                           222":223-223":226-226":229-229")-tetrakisdisulfuro




314
WHO Drug Information Vol. 25, No. 3, 2011                                                                     Recommended INN: List 66


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLQESGPG LVKPSQTLSL TCSFSGFSLS                          TSGMGVGWIR      QPSGKGLEWL    50
                                            AHIWWDGDES YNPSLKSRLT ISKDTSKNQV                          SLKITSVTAA      DTAVYFCARN   100
                                            RYDPPWFVDW GQGTLVTVSS ASTKGPSVFP                          LAPCSRSTSE      STAALGCLVK   150
                                            DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                          GLYSLSSVVT      VTSSNFGTQT   200
                                            YTCNVDHKPS NTKVDKTVER KCCVECPPCP                          APPVAGPSVF      LFPPKPKDTL   250
                                            MISRTPEVTC VVVDVSHEDP EVQFNWYVDG                          MEVHNAKTKP      REEQFNSTFR   300
                                            VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP                          IEKTISKTKG      QPREPQVYTL   350
                                            PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                          ESNGQPENNY      KTTPPMLDSD   400
                                            GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                          LHNHYTQKSL      SLSPG        445

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIQMTQSTSS LSASVGDRVT ITCRASQDIS                          NYLSWYQQKP      GKAVKLLIYY 50
                                            TSKLHSGVPS RFSGSGSGTD YTLTISSLQQ                          EDFATYFCLQ      GKMLPWTFGQ 100
                                            GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                          SVVCLLNNFY      PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                          LSKADYEKHK      VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                                      214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H      22-97           147-203            260-320   366-424
                                                      22''-97''     147''-203''         260''-320''   366''-424''
                                            Intra-L      23'-88'          134'-194'
                                                      23'''-88'''       134'''-194'''
                                            Inter-H-L        134-214'        134''-214'''
                                            Inter-H-H        222-222''        223-223''       226-226''   229-229''


                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            296, 296''


 granotapidum
 granotapide                                diethyl 2-({2-[3-(dimethylcarbamoyl)-4-{4'-(trifluoromethyl)-
                                            [1,1'-biphenyl]-2-carboxamido}phenyl]acetyloxy}methyl)-
                                            2-phenylpropanedioate

 granotapide                                2-[({2-[3-(diméthylcarbamoyl)-4-({[4'-(trifluorométhyl)-[1,1'-biphényl]-
                                            2-yl-carboxamido)phényl]acétyl}oxy)méthyl]-2-phénylpropanedioate
                                            de diéthyle

 granotapida                                2-({2-[3-(dimetilcarbamoil)-4-{4'-(trifluorometil)-[1,1'-bifenil]-
                                            2-carboxamido}fenil]acetiloxi}metil)-2-fenilpropanodioato de dietilo

                                            C39H37F3N2O8

                                               CF3                                      H3C                     CH3
                                                                                                  O O

                                                                                             O              O
                                                                                             O
                                                         O
                                                                                        O
                                                              N
                                                              H
                                                                                   CH3
                                                                    O         N
                                                                              CH3


 icrucumabum #
 icrucumab                                  immunoglobulin G1-kappa, anti-[Homo sapiens FLT1 (fms-related
                                            tyrosine kinase 1, vascular endothelial growth factor receptor 1,
                                            VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor
                                            receptor)], Homo sapiens monoclonal antibody;
                                            gamma1 heavy chain (1-456) [Homo sapiens VH (IGHV3-33*01
                                            (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)],
                                            (229-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                                            V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01) [7.3.9] (1'-108') -
                                            IGKC1*01 (109'-215')]; (235-235'':238-238'')-bisdisulfide dimer




                                                                                                                                         315
Recommended INN: List 66                                      WHO Drug Information Vol. 25, No. 3, 2011




 icrucumab                 immunoglobuline G1 kappa, anti-[Homo sapiens FLT1 (tyrosine
                           kinase 1 apparentée au fms, récepteur 1 du facteur de croissance
                           endothélial vasculaire, VEGFR-1, VEGFR, FLT, FRT, récepteur du
                           facteur de perméabilité vasculaire)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma1 (1-456) [Homo sapiens VH (IGHV3-33*01
                           (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)),
                           (229-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                           sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01) [7.3.9]
                           (1'-108') -IGKC1*01 (109'-215')]; dimère (235-235'':238-238'')-
                           bisdisulfure

 icrucumab                 inmunoglobulina G1 kappa, anti-[Homo sapiens FLT1 (tirosin kinasa
                           1 emparentada con el fms, receptor 1 del factor de crecimiento
                           endotelial vascular, VEGFR-1, VEGFR, FLT, FRT, receptor del
                           factor de permeabilidad vascular)], anticuerpo monoclonal de Homo
                           sapiens;
                           cadena pesada gamma1 (1-456) [Homo sapiens VH (IGHV3-33*01
                           (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)),
                           (229-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                           sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01) [7.3.9]
                           (1'-108') -IGKC1*01 (109'-215')]; dímero (235-235'':238-238'')-
                           bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QAQVVESGGG VVQSGRSLRL SCAASGFAFS                  SYGMHWVRQA       PGKGLEWVAV        50
                           IWYDGSNKYY ADSVRGRFTI SRDNSENTLY                  LQMNSLRAED       TAVYYCARDH       100
                           YGSGVHHYFY YGLDVWGQGT TVTVSSASTK                  GPSVFPLAPS       SKSTSGGTAA       150
                           LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP                  AVLQSSGLYS       LSSVVTVPSS       200
                           SLGTQTYICN VNHKPSNTKV DKRVEPKSCD                  KTHTCPPCPA       PELLGGPSVF       250
                           LFPPKPKDTL MISRTPEVTC VVVDVSHEDP                  EVKFNWYVDG       VEVHNAKTKP       300
                           REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC                  KVSNKALPAP       IEKTISKAKG       350
                           QPREPQVYTL PPSREEMTKN QVSLTCLVKG                  FYPSDIAVEW       ESNGQPENNY       400
                           KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN                  VFSCSVMHEA       LHNHYTQKSL       450
                           SLSPGK                                                                              456

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPGT LSLSPGERAT LSCRASQSVS                  SSYLAWYQQK       PGQAPRLLIY 50
                           GASSRATGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYGSSPLTFG 100
                           GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                           GLSSPVTKSF NRGEC                                                              215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 153-209              270-330  376-434
                                    22''-96'' 153''-209'' 270''-330'' 376''-434''
                           Intra-L 23'-89'      135'-195'
                                    23'''-89''' 135'''-195'''
                           Inter-H-L 229-215' 229''-215'''
                           Inter-H-H 235-235'' 238-238''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           306, 306''



 irosustatum
 irosustat                 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate

 irosustat                 sulfamate de 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromèn-
                           3-yle

 irosustat                 sulfamato de 6-oxo-6,7,8,9,10,11-hexahidrociclohepta[c]cromen-3-ilo




316
WHO Drug Information Vol. 25, No. 3, 2011                                                             Recommended INN: List 66


                                            C14H15NO5S

                                                                      O          NH2
                                                                             S
                                                                        O O

                                                             O

                                                         O

 ivacaftorum
 ivacaftor                                  N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-
                                            3-carboxamide

 ivacaftor                                  N-[2,4-di-tert-butyl-5-hydroxyphényl]-4-oxo-1,4-dihydroquinoléine-
                                            3-carboxamide

 ivacaftor                                  N-(2,4-di-terc-butil-5-hidroxifenil)-4-oxo-1,4-dihidroquinolina-
                                            3-carboxamida

                                            C24H28N2O3

                                                     H                           CH3
                                                     N                H3 C
                                                                                     CH3
                                                                  H
                                                                  N
                                                                                           CH3
                                                     O        O
                                                                                            CH3
                                                                             OH        CH3


 ixazomibum
 ixazomib                                   {(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic
                                            acid

 ixazomib                                   acide [(1R)-1-{[N-(2,5-dichlorobenzoyl)glycyl]amino}-
                                            3-méthylbutyl]boronique

 ixazomib                                   acido {(1R)-1-[(2,5-diclorobenzamido)acetamido]-
                                            3-metilbutil]borónico

                                            C14H19BCl2N2O4

                                                             O                             OH
                                                                                 H
                                            Cl                                   N         B
                                                                  N                             OH
                                                                  H                        H
                                                                             O                  CH3
                                                             Cl
                                                                                           CH3


 lenvatinibum
 lenvatinib                                 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-
                                            7-methoxyquinoline-6-carboxamide

 lenvatinib                                 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phénoxy}-
                                            7-méthoxyquinoléine-6-carboxamide

 lenvatinib                                 4-{3-cloro-4-[(ciclopropilcarbamoil)amino]fenoxi}-7-metoxiquinolina-
                                            6-carboxamida




                                                                                                                           317
Recommended INN: List 66                                  WHO Drug Information Vol. 25, No. 3, 2011


                           C21H19ClN4O4

                             H3CO              N

                           H2N

                                  O           O
                                                                     O

                                                                 N       N
                                                                 H       H
                                                     Cl



 letaxabanum
 letaxaban                 1-(1-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-
                           2-hydroxypropanoyl}piperidin-4-yl)tetrahydropyrimidin-2(1H)-one

 létaxaban                 1-(1-{(2S)-3-[(6-chloronaphtalén-2-yl)sulfonyl]-
                           2-hydroxypropanoyl}pipéridin-4-yl)tétrahydropyrimidin-2(1H)-one

 letaxabán                 1-(1-{(2S)-3-[(6-cloronaftalen-2-il)sulfonil]-
                           2-hidroxipropanoil}piperidin-4-il)tetrahidropirimidin-2(1H)-ona

                           C22H26ClN3O5S

                                                                                Cl
                                               O

                                          N                  S
                                              HO H O O
                                  N

                              N       O
                              H



 letermovirum
 letermovir                (4S)-2-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-
                           5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid

 létermovir                acide {(4S)-8-fluoro-2-[4-(3-méthoxyphényl)pipérazin-1-yl]-
                           3-[2-méthoxy-5-(trifluorométhyl)phényl]-3,4-dihydroquinazolin-
                           4-yl}acétique

 letermovir                ácido (4S)-2-{8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-
                           5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il}acético

                           C29H28F4N4O4

                                                   F3C


                           H3CO            N                          OCH3
                                                                     H
                                                    N        N

                                                         N               CO2H


                                                         F




318
WHO Drug Information Vol. 25, No. 3, 2011                                                Recommended INN: List 66


 levoglucosum
 levoglucose                                L-glucose

 lévoglucose                                L-glucose

 levoglucosa                                L-glucosa

                                            C6H12O6

                                             HO        O
                                                       HO     OH
                                            HO
                                                  OH

 linsitinibum
 linsitinib                                 (1s,3r)-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-
                                            3-yl]-1-methylcyclobutan-1-ol

 linsitinib                                 (1s,3r)-3-[8-amino-1-(2-phénylquinoléin-7-yl)imidazo[1,5-a]pyrazin-
                                            3-yl]-1-méthylcyclobutan-1-ol

 linsitinib                                 (1s,3r)-3-[8-amino-1-(2-fenilquinolin-7-il)imidazo[1,5-a]pirazin-3-il]-
                                            1-metilciclobutan-1-ol

                                            C26H23N5O

                                                                   N
                                                  OH
                                            H3C                        NH2
                                                             N

                                                                             N
                                                        H     N




 luseogliflozinum
 luseogliflozin                             (2S,3R,4R,5S,6R)-2-{5-[(4-ethoxyphenyl)methyl]-2-methoxy-
                                            4-methylphenyl}-6-(hydroxymethyl)thiane-3,4,5-triol

 luséogliflozine                            (2S,3R,4R,5S,6R)-2-{5-[(4-éthoxyphényl)méthyl]-2-méthoxy-
                                            4-méthylphényl}-6-(hydroxyméthyl)thiane-3,4,5-triol

 luseogliflozina                            (2S,3R,4R,5S,6R)-2-{5-[(4-etoxifenil)metil]-4-metilfenil-2-metoxi}-
                                            6-(hidroximetil)tiano-3,4,5-triol

                                            C23H30O6S

                                                   O        CH3




                                                            CH3

                                            HO

                                                        S         OCH3

                                                  OH
                                            HO
                                                        OH




                                                                                                                      319
Recommended INN: List 66                              WHO Drug Information Vol. 25, No. 3, 2011


 lusutrombopagum
 lusutrombopag             (2E)-3-{2,6-dichloro-4-[(4-{3-[(1S)-1-(hexyloxy)ethyl]-
                           2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-
                           2-enoic acid

 lusutrombopag             acide (2E)-3-{2,6-dichloro-4-[(4-{3-[(1S)-1-(hexyloxy)éthyl]-
                           2-méthoxyphényl}-1,3-thiazol-2-yl)carbamoyl]phényl}-2-méthylprop-
                           2-énoïque

 lusutrombopag             ácido (2E)-3-{2,6-dicloro-4-[(4-{3-[(1S)-1-(hexiloxi)etil]-2-metoxifenil}-
                           1,3-tiazol-2-il)carbamoil]fenil}-2-metilprop-2-enoico

                           C29H32Cl2N2O5S

                                                                    S       O
                                                                                     Cl
                                                                N       N                 CH3
                                                                        H
                                                           OCH3                             CO2H
                                                          CH3                   Cl
                           H3 C                  O
                                                      H

 mavoglurantum
 mavoglurant               methyl (3aR,4S,7aR)-4-hydroxy-
                           4-[2-(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylate

 mavoglurant               (3aR,4S,7aR)-4-hydroxy-4-[2-(3-méthylphényl)éthynyl]octahydro-
                           1H-indole-1-carboxylate de méthyle

 mavoglurant               (3aR,4S,7aR)-4-hidroxi-4-[2-(3-metilfenil)etinil]octahidro-1H-indol-
                           1-carboxilato de metil

                           C19H23NO3


                                                  H        H    O

                                            HO             N
                                                                    O CH3
                           H3C


 mogamulizumabum #
 mogamulizumab             immunoglobulin G1-kappa, anti-[Homo sapiens CCR4 (chemokine
                           (C-C motif) receptor 4, CC chemokine receptor 4, CCR-4, CKR4,
                           k5-5, CD194)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                           IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-219')-disulfide with kappa light
                           chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-29*02
                           (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                           (113'-219')]; (228-228":231-231")-bisdisulfide dimer

 mogamulizumab             immunoglobuline G1-kappa, anti-[Homo sapiens CCR4 (récepteur 4
                           de chimiokine (C-C motif), récepteur 4 de chimiokine CC, CCR-4,
                           CKR4, k5-5, CD194)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                           IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne
                           légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-
                           29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                           IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure




320
WHO Drug Information Vol. 25, No. 3, 2011                                                             Recommended INN: List 66




 mogamulizumab                              inmunoglobulina G1-kappa, anti-[CCR4 de Homo sapiens (receptor
                                            4 de quimiokina (C-C motif), receptor 4 de quimiokina CC, CCR-4,
                                            CKR4, k5-5, CD194)], anticuerpo monoclonal humanizado;
                                            cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens
                                            IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                                            sapiens IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena
                                            ligera kappa (1'-219') [V-KAPPA humanizada (Homo sapiens IGKV2-
                                            29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                                            IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGD LVQPGRSLRL SCAASGFIFS                  NYGMSWVRQA       PGKGLEWVAT        50
                                            ISSASTYSYY PDSVKGRFTI SRDNAKNSLY                  LQMNSLRVED       TALYYCGRHS       100
                                            DGNFAFGYWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                            ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                            YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                            Light chain / Chaîne légère / Cadena ligera
                                            DVLMTQSPLS LPVTPGEPAS ISCRSSRNIV                  HINGDTYLEW       YLQKPGQSPQ 50
                                            LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCFQGSLLP 100
                                            WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                            VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                            VTHQGLSSPV TKSFNRGEC                                                          219

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        146-202       263-323  369-427
                                                      22''-96'' 146''-202'' 263''-323'' 369''-427''
                                            Intra-L 23'-93'      139'-199'
                                                     23'''-93''' 139'''-199'''
                                            Inter-H-L 222-219' 222''-219'''
                                            Inter-H-H 228-228'' 231-231''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            299, 299''




 namilumabum #
 namilumab                                  immunoglobulin G1-kappa, anti-[Homo sapiens CSF2 (Homo
                                            sapiens colony stimulating factor 2 (granulocyte-macrophage),
                                            granulocyte-macrophage colony stimulating factor, GM-CSF)], Homo
                                            sapiens monoclonal antibody;
                                            gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV1-2*02
                                            (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) -
                                            IGHG1*01 (120-449)], (222-214')-disulfide with kappa light chain
                                            (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (88.40%) -
                                            IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228'':231-
                                            231'')-bisdisulfide dimer

 namilumab                                  immunoglobuline G1-kappa, anti-[Homo sapiens CSF2 (Homo
                                            sapiens facteur 2 stimulant de colonies (granulocyte-macrophage),
                                            facteur stimulant des colonies de granulocytes et macrophages,
                                            GM-CSF)], Homo sapiens anticorps monoclonal;
                                            chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV1-2*02
                                            (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) -
                                            IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne légère
                                            kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (88.40%) -
                                            IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-
                                            228'':231-231'')-bisdisulfure




                                                                                                                                          321
Recommended INN: List 66                                     WHO Drug Information Vol. 25, No. 3, 2011


 namilumab                 inmunoglobulina G1-kappa, anti-[CSF2 de Homo sapiens (Homo
                           sapiens factor 2 estimulante de colonias (granulocito-macrófago),
                           factor estimulante de colonias de granulocitos y macrófagos,
                           GM-CSF)], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV1-2*02
                           (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) -
                           IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena ligera
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (88.40%) -
                           IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-
                           228'':231-231'')-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKAFGYPFT                  DYLLHWVRQA       PGQGLEWVGW        50
                           LNPYSGDTNY AQKFQGRVTM TRDTSISTAY                  MELSRLRSDD       TAVYYCTRTT       100
                           LISVYFDYWG QGTMVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS VSASVGDRVT IACRASQNIR                  NILNWYQQRP       GKAPQLLIYA 50
                           ASNLQSGVPS RFSGSGSGTD FTLTINSLQP                  EDFATYYCQQ       SYSMPRTFGG 100
                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202       263-323  369-427
                                     22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-88' 134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 222-214' 222''-214'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''



 naronapridum
 naronapride               (3R)-1-azabicyclo[2.2.2]octan-3-yl 6-[(3S,4R)-4-(4-amino-5-chloro-
                           2-methoxybenzamido)-3-methoxypiperidin-1-yl]hexanoate

 naronapride               6-{(3S,4R)-4-(4-amino-5-chloro-2-méthoxybenzamido)-
                           3-méthoxypipéridin-1-yl}hexanoate de (3R)-1-azabicyclo[2.2.2]oct-
                           3-yl

 naronaprida               6-[(3S,4R)-4-(4-amino-5-cloro-2-metoxibenzamido)-
                           3-metoxipiperidin-1-il]hexanoato de (3R)-1-azabiciclo[2.2.2]octan-
                           3-ilo

                           C27H41ClN4O5

                                                                                          O
                                              O               N
                                                  H                                       H
                            Cl                                                        O               N
                                                  N
                                                  H
                                                        H OCH3
                           H2N                OCH3




322
WHO Drug Information Vol. 25, No. 3, 2011                                            Recommended INN: List 66




 onartuzumabum #
 onartuzumab                                immunoglobulin G1-kappa monovalent Fab-Fc, anti-[Homo sapiens
                                            MET (met proto-oncogene, hepatocyte growth factor receptor,
                                            HGFR, scatter factor receptor, HGF/SF receptor, receptor tyrosine-
                                            protein kinase c-Met, papillary renal cell carcinoma 2, RCCP2)],
                                            humanized monoclonal antibody;
                                            gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                                            IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                                            sapiens IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368),
                                            L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfide with
                                            kappa light chain (1'-220') [humanized V-KAPPA (Homo sapiens
                                            IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiens
                                            IGKC*01 (114'-220')], (228-6'':231-9'')-bisdisulfide with truncated
                                            gamma1 chain consisting of partial hinge-CH2-CH3 (1"-227") [Homo
                                            sapiens IGHG1*01 hinge 6-15(1"-10")-CH2(11"-120")-CH3(121"-
                                            227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]

 onartuzumab                                immunoglobuline G1-kappa monovalent Fab-Fc, anti-[Homo sapiens
                                            MET (proto-oncogène met, récepteur du facteur de croissance
                                            hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur
                                            de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome
                                            papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal
                                            humanisé;
                                            chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                                            IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                                            sapiens IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368),
                                            L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfure avec la
                                            chaîne légère kappa (1'-220') [V-KAPPA humanisé (Homo sapiens
                                            IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiens
                                            IGKC*01 (114'-220')], (228-6'':231-9'')-bisdisulfure avec la chaîne
                                            gamma1 tronquée comprenant charnière partielle-CH2-CH3 (1"-
                                            227") [Homo sapiens IGHG1*01 charnière 6-15(1"-10")-CH2(11"-
                                            120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W
                                            (146")]

 onartuzumab                                inmunoglobulina G1-kappa monovalente Fab-Fc, anti-[Homo
                                            sapiens MET (protooncogén met, receptor del factor de crecimiento
                                            hepatocitario, HGFR, receptor del factor de dispersión, receptor de
                                            l'HGF/SF, receptor de tirosina proteín-kinasa c-Met, carcinoma
                                            papilar de cèlulas renales 2, RCCP2)], anticuerpo monoclonal
                                            humanizado;
                                            cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens
                                            IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                                            sapiens IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368),
                                            L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfuro con la
                                            cadena ligera kappa (1'-220') [V-KAPPA humanizada (Homo sapiens
                                            IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiens
                                            IGKC*01 (114'-220')], (228-6'':231-9'')-bisdisulfuro con la cadena
                                            gamma1 truncada que comprende parte de la bisagra-CH2-CH3
                                            (1"-227") [Homo sapiens IGHG1*01 bisagra 6-15(1"-10")-CH2(11"-
                                            120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W
                                            (146")]




                                                                                                              323
Recommended INN: List 66                                     WHO Drug Information Vol. 25, No. 3, 2011




                           Heavy chain / Chaîne lourde / Cadena pesada (H)
                           EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYWLHWVRQA                        PGKGLEWVGM        50
                           IDPSNSDTRF NPNFKDRFTI SADTSKNTAY LQMNSLRAED                        TAVYYCATYR       100
                           SYVTPLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG                        TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV                        PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP                        SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK                        TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK                        AKGQPREPQV       350
                           YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE                        NNYKTTPPVL       400
                           DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ                        KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera (L)
                           DIQMTQSPSS LSASVGDRVT ITCKSSQSLL                  YTSSQKNYLA       WYQQKPGKAP 50
                           KLLIYWASTR ESGVPSRFSG SGSGTDFTLT                  ISSLQPEDFA       TYYCQQYYAY 100
                           PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ                  LKSGTASVVC       LLNNFYPREA 150
                           KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                  LSSTLTLSKA       DYEKHKVYAC 200
                           EVTHQGLSSP VTKSFNRGEC                                                         220

                           Hinge-CH2-CH3 / Charnière-CH2-CH3/ Bisagra-CH2-CH3 (H'')
                           DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT                        CVVVDVSHED 50
                           PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH                        QDWLNGKEYK 100
                           CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK                        NQVSLWCLVK 150
                           GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL                        TVDKSRWQQG 200
                           NVFSCSVMHE ALHNHYTQKS LSLSPGK                                                 227

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202 263-323 369-427
                           Intra-H'' 41''-101'' 147''-205''
                           Intra-L 23'-94'      140'-200'
                           Inter-H-L 222-220'
                           Inter-H-H'' 228-6'' 231-9''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 77'' unglycosylated as expressed in Escherichia coli


 orteronelum
 orteronel                 6-[(7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-
                           N-methylnaphthalene-2-carboxamide

 ortéronel                 6-[(7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-
                           N-méthylnaphtalène-2-carboxamide

 orteronel                 6-[(7S)-7-hidroxi-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-7-il]-
                           N-metilnaftaleno-2-carboxamida

                           C18H17N3O2

                                                                     N

                                                        HO           N

                                  H
                                  N
                           H3C
                                      O

 pacritinibum
 pacritinib                ((2E,16E)-11-[2-(pyrrolidin-1-yl)ethoxy]-14,19-dioxa-
                                                            2,6 8,12
                           5,7,27-triazatetracyclo[19.3.1.1 .1 ]heptacosa-
                           1(25),2,4,6,8,10,12(26),16,21,23-decaene

 pacritinib                (16E)-11-[2-(pyrrolidin-1-yl)éthoxy]-14,19-dioxa-
                                                            2,6 8,12
                           5,7,27-triazatétracyclo[19.3.1.1 .1 ]heptacosa-
                           1(24),2,4,6,8,10,12(26),16,21(25),22-décaène

 pacritinib                ((2E,16E)-11-[2-(pirrolidin-1-il)etoxi]-14,19-dioxa-
                                                             2,6 8,12
                           5,7,27-triazatetraciclo[19.3.1. 1 .1 ]heptacosa
                           1(25),2,4,6,8,10,12(26),16,21,23-decaeno




324
WHO Drug Information Vol. 25, No. 3, 2011                                                            Recommended INN: List 66




                                            C28H32N4O3



                                                       O

                                                                         HN        N

                                                                              N
                                                           O
                                                  N
                                                               O



 plecanatidum
 plecanatide                                [3-glutamic acid(D>E)]human uroguanylin (UGN)

 plécanatide                                [3-acide glutamique(D>E)]uroguanyline humaine (UGN)

 plecanatida                                [3-ácido glutámico(D>E)]uroguanilina humana (UGN)

                                            C65H104N18O26S4

                                            NDECELCVNV ACTGCL                                                                         16

                                            Disulfide bridges location / Position des ponts disulfure/ Posiciones de los puentes disulfuros
                                            4-12 7-15



 pomaglumetadum methionilum
                                                                                                               6
 pomaglumetad methionil                     (1R,4S,5S,6S)-4-(L-methionylamino)-2,2-dioxo-2λ -
                                            thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
                                                                                                                         6
 pomaglumétad méthionil                     acide (1R,4S,5S,6S)-4-(L-méthionylamino)-2,2-dioxo-2λ -
                                            thiabicyclo[3.1.0]hexane-4,6-dicarboxylique
                                                                                                                     6
 pomaglumetad metionilo                     ácido (1R,4S,5S,6S)-4-(L-metionilamino)-2,2-dioxo-2λ -
                                            tiabiciclo[3.1.0]hexano-4,6-dicarboxílico

                                            C12H18N2O7S2

                                                                     O        H     CO2H
                                                                   O
                                                                      S                 H
                                                                   O
                                                                                    H
                                                   S
                                            H3C                          N        CO2H
                                                                         H
                                                               H   NH2



 ponatinibum
 ponatinib                                  3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-
                                            methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide

 ponatinib                                  3-[2-(imidazo[1,2-b]pyridazin-3-yl)éthynyl]-4-méthyl-N-{4-[(4-
                                            méthylpipérazin-1-yl)méthyl]-3-(trifluorométhyl)phényl}benzamide

 ponatinib                                  3-[2-(imidazo[1,2-b]piridazin-3-il)etinil]-4-metil-N-{4-[(4-
                                            metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida




                                                                                                                                        325
Recommended INN: List 66                                         WHO Drug Information Vol. 25, No. 3, 2011


                           C29H27F3N6O

                                          H3C
                                                                  H
                                                                  N                 CF3              CH3
                                                                                                 N
                                                             O                          N
                           N
                                  N
                                      N



 ponezumabum #
 ponezumab                 immunoglobulin G2-kappa, anti-[Homo sapiens amyloid beta
                           (A beta) peptide Aβ40], humanized monoclonal antibody;
                           gamma2 heavy chain (1-442) [humanized VH (Homo sapiens
                           IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -Homo
                           sapiens IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)],
                           (130-219')-disulfide with kappa light chain (1'-219') [humanized
                           V-KAPPA (Homo sapiens IGKV2-30*01 (89.00%) -IGKJ5*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (218-
                           218":219-219":222-222":225-225")-tetrakisdisulfide dimer

 ponezumab                 immunoglobuline G2-kappa, anti-[Homo sapiens peptide amyloïde
                           bêta (A bêta) Aβ40], anticorps monoclonal humanisé;
                           chaîne lourde gamma2 (1-442) [VH humanisé (Homo sapiens
                           IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -Homo
                           sapiens IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)],
                           (130-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
                           humanisé (Homo sapiens IGKV2-30*01 (89.00%) -IGKJ5*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (218-
                           218":219-219":222-222":225-225")-tétrakisdisulfure

 ponezumab                 inmunoglobulina G2-kappa, anti-[péptido amiloide beta de Homo
                           sapiens (A beta) Aβ40], anticuerpo monoclonal humanizado;
                           cadena pesada gamma2 (1-442) [VH humanizada (Homo sapiens
                           IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -Homo
                           sapiens IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)],
                           (130-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                           humanizada (Homo sapiens IGKV2-30*01 (89.00%) -IGKJ5*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímer (218-
                           218":219-219":222-222":225-225")-tetrakisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYYTE                  AYYIHWVRQA       PGQGLEWMGR        50
                           IDPATGNTKY APRLQDRVTM TRDTSTSTVY                  MELSSLRSED       TAVYYCASLY       100
                           SLPVYWGQGT TVTVSSASTK GPSVFPLAPC                  SRSTSESTAA       LGCLVKDYFP       150
                           EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       NFGTQTYTCN       200
                           VDHKPSNTKV DKTVERKCCV ECPPCPAPPV                  AGPSVFLFPP       KPKDTLMISR       250
                           TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH                  NAKTKPREEQ       FNSTFRVVSV       300
                           LTVVHQDWLN GKEYKCKVSN KGLPSSIEKT                  ISKTKGQPRE       PQVYTLPPSR       350
                           EEMTKNQVSL TCLVKGFYPS DIAVEWESNG                  QPENNYKTTP       PMLDSDGSFF       400
                           LYSKLTVDKS RWQQGNVFSC SVMHEALHNH                  YTQKSLSLSP       GK               442

                           Light chain / Chaîne légère / Cadena ligera
                           DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL                  YSDAKTYLNW       FQQRPGQSPR 50
                           RLIYQISRLD PGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCLQGTHYP 100
                           VLFGQGTRLE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H    22-96        143-199         256-316      362-420
                                    22''-96''   143''-199''    256''-316''    362''-420''
                           Intra-L    23'-93'       139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L      130-219'    130''-219'''
                           Inter-H-H      218-218''    219-219''      222-222''   225-225''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           292, 292''




326
WHO Drug Information Vol. 25, No. 3, 2011                                                          Recommended INN: List 66


 pracinostatum
 pracinostat                                (2E)-3-{2-butyl-1-[2-(dimethylamino)ethyl]-1H-benzimidazol-5-yl}-
                                            N-hydroxyprop-2-enamide

 pracinostat                                (2E)-3-{2-butyl-1-[2-(diéthylamino)éthyl]-1H-benzimidazol-5-yl]-
                                            N-hydroxyprop-2-énamide

 pracinostat                                (2E)-3-{2-butil-1-[2-(dimetilamino)etil]-1H-bencimidazol-5-il}-
                                            N-hidroxyprop-2-enamida

                                            C20H30N4O2


                                                    H3C                  N
                                                                  N
                                            H3C
                                                         N                               H
                                                                                         N
                                                                                             OH
                                             H3C
                                                                                     O

 quizartinibum
 quizartinib                                1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-
                                            4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea

 quizartinib                                N-[5-tert-butyl-1,2-oxazol-3-yl]-N'-(4-{7-[2-(morpholin-
                                            4-yl)éthoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phényl)urée

 quizartinib                                1-(5-terc-butil-1,2-oxazol-3-il)-3-(4-{7-[2-(morfolin-
                                            4-il)etoxi]imidazo[2,1-b][1,3]benzotiazol-2-il}fenil)urea

                                            C29H32N6O4S

                                                                 O           S
                                                     N
                                                                                                                 H3 C         CH3
                                            O                                        N
                                                                             N
                                                                                                                              CH3
                                                                                                        O
                                                                                                                          O
                                                                                                    N       N         N
                                                                                                    H       H

 radotinibum
 radotinib                                  4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-
                                            3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide

 radotinib                                  4-méthyl-N-[3-(4-méthyl-1H-imidazol-1-yl)-5-(trifluorométhyl)phényl]-
                                            3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide

 radotinib                                  4-metil-N-[3-(4-metil-1H-imidazol-1-il)-5-(trifluorometil)fenil]-
                                            3-{[4-(pirazin-2-il)pirimidin-2-il]amino}benzamida

                                            C27H21F3N8O

                                                                 H3C                                    N
                                                                 N
                                                                                     H                          CH3
                                                N                                    N              N
                                                             N       N
                                                                     H
                                                                                 O
                                                N
                                                                                             CF3




                                                                                                                                    327
Recommended INN: List 66                                    WHO Drug Information Vol. 25, No. 3, 2011


 radretumabum #
 radretumab                immunoglobulin scFv-CH dimer, anti-[Homo sapiens fibronectin extra
                           domain B (ED-B)], Homo sapiens monoclonal antibody fragment
                           dimer of single chain (scFv) fused with the IGHE CH4;
                           scFv-CH (1-357) [Homo sapiens VH (IGHV3-23*01 (94.90%) -
                           (IGHD)-IGHJ4*01) [8.8.14] (1-116)-12-mer linker (117-128)- Homo
                           sapiens V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-
                           236)-5-mer linker (237-241)- Homo sapiens IGHE*01 CH4 (242-
                           349)-8-mer linker (350-357)]; (357:357') disulfide dimer

 radrétumab                immunoglobuline scFv-CH dimère, anti-[Homo sapiens extra
                           domaine B (ED-B) de la fibronectine], Homo sapiens anticorps
                           monoclonal fragment dimère de scFv fusionné au CH4 de l'IGHE;
                           scFv-CH (1-357) [Homo sapiens VH (IGHV3-23*01 (94.90%) -
                           (IGHD)-IGHJ4*01) [8.8.14] (1-116)-12-mer linker (117-128)- Homo
                           sapiens V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-
                           236)-5-mer linker (237-241)- Homo sapiens IGHE*01 CH4 (242-
                           349)-8-mer linker (350-357)]; dimère (357:357')

 radretumab                inmunoglobulina scFv-CH dímero, anti-[Homo sapiens extra dominio
                           B (ED-B) de la fibronectina], fragmento de anticuerpo monoclonal de
                           Homo sapiens dímero de scFv fusionado con el CH4 del IGHE;
                           scFv-CH (1-357) [Homo sapiens VH (IGHV3-23*01 (94.90%) -
                           (IGHD)-IGHJ4*01) [8.8.14] (1-116)-dodecámero de conexión (117-
                           128)- Homo sapiens V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01)
                           [7.3.9] (129-236)-pentámero de conexión (237-241)- Homo sapiens
                           IGHE*01 CH4 (242-349)-octámero de conexión (350-357)]; dímero
                           (357:357') disulfuro


                           scFv-CH chain / Chaîne scFv-CH / Cadena scFv-CH
                           EVQLLESGGG LVQPGGSLRL SCAASGFTFS SFSMSWVRQA                        PGKGLEWVSS        50
                           ISGSSGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED                        TAVYYCAKPF       100
                           PYFDYWGQGT LVTVSSGDGS SGGSGGASEI VLTQSPGTLS                        LSPGERATLS       150
                           CRASQSVSSS FLAWYQQKPG QAPRLLIYYA SSRATGIPDR                        FSGSGSGTDF       200
                           TLTISRLEPE DFAVYYCQQT GRIPPTFGQG TKVEIKSGGS                        GGPRAAPEVY       250
                           AFATPEWPGS RDKRTLACLI QNFMPEDISV QWLHNEVQLP                        DARHSTTQPR       300
                           KTKGSGFFVF SRLEVTRAEW EQKDEFICRA VHEAASPSQT                        VQRAVSVNPE       350
                           SSRRGGC                                                                             357

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-chain 22-96 151-217 268-328
                                        22'-96' 151'-217' 268'-328'
                           Inter-chain 357-357'


 selurampanelum
 selurampanel              N-[6-(1-methyl-1H-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-
                           1,4-dihydroquinazolin-3(2H)-yl]methanesulfonamide

 sélurampanel              N-[6-(1-méthyl-1H-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-
                           1,4-dihydroquinazolin-3(2H)-yl]méthanesulfonamide

 selurampanel              N-[6-(1-metil-1H-pirazol-5-il)-7-(propan-2-il)-2,4-dioxo-
                           1,4-dihidroquinazolin-3(2H)-il]metanosulfonamida

                           C16H19N5O4S

                                  CH3
                                                  H
                                                  N     O
                           H3 C                          O O
                                                      N   S
                                                        N   CH3
                                                        H
                             N N                 O
                                     CH3




328
WHO Drug Information Vol. 25, No. 3, 2011                                               Recommended INN: List 66


 setipiprantum
 setipiprant                                [8-fluoro-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-
                                            5H-pyrido[4,3-b]indol-5-yl]acetic acid

 sétipiprant                                acide 2-[8-fluoro-2-(naphtalén-1-ylcarbonyl)-1,2,3,4-tétrahydro-
                                            5H-pyrido[4,3-b]indol-5-yl]acétique

 setipiprant                                ácido {8-fluoro-2-(naftalen-1-carbonil)-1,2,3,4-tetrahidro-
                                            5H-pirido[4,3-b]indol-5-il}acético

                                            C24H19FN2O3

                                                                      CO2H

                                                                 N

                                                         N

                                                     O
                                                                        F

 silmitasertibum
 silmitasertib                              5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic
                                            acid

 silmitasertib                              acide 5-[(3-chlorophényl)amino]benzo[c][2,6]naphtyridine-
                                            8-carboxylique

 silmitasertib                              ácido 5-[(3-clorofenil)amino]benzo[c][2,6]naftiridina-8-carboxílico

                                            C19H12ClN3O2

                                                     H
                                                     N       N         CO2H




                                               Cl
                                                         N

 simoctocogum alfa #
 simoctocog alfa                            B-domain deleted human coagulation factor VIII;
                                            [749-glutamine,750-alanine-751-tyrosine-753-tyrosine-754-arginine-
                                            755-arginine-756-glycine]human coagulation factor VIIIa heavy
                                            chain-(1-756)-peptide (containing F5/8 type A 1 and A 2 domains)
                                            fusion protein with human coagulation factor VIIIa light chain,
                                            glycosylated

 simoctocog alfa                            facteur VIII de coagulation humain dont le domaine B a été
                                            supprimé;
                                            [749-glutamine,750-alanine-751-tyrosine-753-tyrosine-754-arginine-
                                            755-arginine-756-glycine]chaîne lourde du facteur VIIIa de
                                            coagulation humain-(1-756)-peptide (contenant les domaines F5/8
                                            type A 1 and A 2) protéine de fusion avec la chaîne légère du facteur
                                            VIIIa de coagulation humain glycosylé

 simoctocog alfa                            factor VIII de coagulación humano cuyo dominio B se ha suprimido;
                                            [749-glutamina,750-alanina-751-tirosina-753-tirosina-754-arginina-
                                            755-arginina-756-glicina]cadena pesada del factor VIIIa de
                                            coagulación humano-(1-756)-péptido (contiene los dominios F5/8
                                            tipo A 1 y A 2) proteína de fusión con la cadena ligera del factor VIIIa
                                            de coagulación humano glicosilado



                                                                                                                  329
Recommended INN: List 66                                           WHO Drug Information Vol. 25, No. 3, 2011


                                 C7459H11338N1992O2188S68 (peptide)

                                 ATRRYYLGAV      ELSWDYMQSD       LGELPVDARF       PPRVPKSFPF       NTSVVYKKTL       50
                                 FVEFTDHLFN      IAKPRPPWMG       LLGPTIQAEV       YDTVVITLKN       MASHPVSLHA       100
                                 VGVSYWKASE      GAEYDDQTSQ       REKEDDKVFP       GGSHTYVWQV       LKENGPMASD       150
                                 PLCLTYSYLS      HVDLVKDLNS       GLIGALLVCR       EGSLAKEKTQ       TLHKFILLFA       200
                                 VFDEGKSWHS      ETKNSLMQDR       DAASARAWPK       MHTVNGYVNR       SLPGLIGCHR       250
                                 KSVYWHVIGM      GTTPEVHSIF       LEGHTFLVRN       HRQASLEISP       ITFLTAQTLL       300
                                 MDLGQFLLFC      HISSHQHDGM       EAYVKVDSCP       EEPQLRMKNN       EEAEDYDDDL       350
                                 TDSEMDVVRF      DDDNSPSFIQ       IRSVAKKHPK       TWVHYIAAEE       EDWDYAPLVL       400
                                 APDDRSYKSQ      YLNNGPQRIG       RKYKKVRFMA       YTDETFKTRE       AIQHESGILG       450
                                 PLLYGEVGDT      LLIIFKNQAS       RPYNIYPHGI       TDVRPLYSRR       LPKGVKHLKD       500
                                 FPILPGEIFK      YKWTVTVEDG       PTKSDPRCLT       RYYSSFVNME       RDLASGLIGP       550
                                 LLICYKESVD      QRGNQIMSDK       RNVILFSVFD       ENRSWYLTEN       IQRFLPNPAG       600
                                 VQLEDPEFQA      SNIMHSINGY       VFDSLQLSVC       LHEVAYWYIL       SIGAQTDFLS       650
                                 VFFSGYTFKH      KMVYEDTLTL       FPFSGETVFM       SMENPGLWIL       GCHNSDFRNR       700
                                 GMTALLKVSS      CDKNTGDYYE       DSYEDISAYL       LSKNNAIEPR       SFSQNSRHQA       750
                                 YRYRRGEITR      TTLQSDQEEI       DYDDTISVEM       KKEDFDIYDE       DENQSPRSFQ       800
                                 KKTRHYFIAA      VERLWDYGMS       SSPHVLRNRA       QSGSVPQFKK       VVFQEFTDGS       850
                                 FTQPLYRGEL      NEHLGLLGPY       IRAEVEDNIM       VTFRNQASRP       YSFYSSLISY       900
                                 EEDQRQGAEP      RKNFVKPNET       KTYFWKVQHH       MAPTKDEFDC       KAWAYFSDVD       950
                                 LEKDVHSGLI      GPLLVCHTNT       LNPAHGRQVT       VQEFALFFTI       FDETKSWYFT       1000
                                 ENMERNCRAP      CNIQMEDPTF       KENYRFHAIN       GYIMDTLPGL       VMAQDQRIRW       1050
                                 YLLSMGSNEN      IHSIHFSGHV       FTVRKKEEYK       MALYNLYPGV       FETVEMLPSK       1100
                                 AGIWRVECLI      GEHLHAGMST       LFLVYSNKCQ       TPLGMASGHI       RDFQITASGQ       1150
                                 YGQWAPKLAR      LHYSGSINAW       STKEPFSWIK       VDLLAPMIIH       GIKTQGARQK       1200
                                 FSSLYISQFI      IMYSLDGKKW       QTYRGNSTGT       LMVFFGNVDS       SGIKHNIFNP       1250
                                 PIIARYIRLH      PTHYSIRSTL       RMELMGCDLN       SCSMPLGMES       KAISDAQITA       1300
                                 SSYFTNMFAT      WSPSKARLHL       QGRSNAWRPQ       VNNPKEWLQV       DFQKTMKVTG       1350
                                 VTTQGVKSLL      TSMYVKEFLI       SSSQDGHQWT       LFFQNGKVKV       FQGNQDSFTP       1400
                                 VVNSLDPPLL      TRYLRIHPQS       WVHQIALRME       VLGCEAQDLY                        1440

                                 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                 153-179 248-329 528-554 630-711 940-966 1007-1011 1129-1277 1282-1434

                                 Sulfated residues (Y) / Résidus sulfatés (Y) / Reioduos sulfatados (Y)
                                 Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-772 Tyr-788

                                 Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                 Asn-41 Asn-239 Asn-918 Asn-1226


 talimogenum laherparepvecum #
 talimogene laherparepvec        recombinant replicating Herpes simplex type -1 virus vector, with
                                 ICP47 and both copies of ICP34.5 genes deleted, expressing human
                                 granulocyte macrophage colony stimulating factor (hGM-CSF) in the
                                 ICP34.5 loci

 talimogène laherparépvec        vecteur viral Herpes simplex type 1 répliquant avec délétion du gène
                                 ICP47 et des deux copies du gène ICP34.5, exprimant le facteur
                                 humain de développement des polynucléaires et des macrophages
                                 (hGM-CSF) dans les loci ICP34.5

 talimogén laherparepvec         vector virus del Herpes simplex tipo-1 replicante recombinante con
                                 delección del gen ICP47 y las dos copias del gen ICP34.5, que
                                 expresa el factor humano estimulante de colonias de granulocitos y
                                 macrógafos (hGM-CSF) in los loci ICP34.5


 tedizolidum
 tedizolid                       (5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-
                                 5-(hydroxymethyl)-1,3-oxazolidin-2-one

 tédizolid                       (5R)-3-{3-fluoro-4-[6-(2-méthyl-2H-tétrazol-5-yl)pyridin-3-yl]phényl}-
                                 5-(hydroxyméthyl)-1,3-oxazolidin-2-one

 tedizolid                       (5R)-3-{3-fluoro-4-[6-(2-metil-2H-tetrazol-5-il)piridin-3-il]fenil}-
                                 5-(hidroximetil)-1,3-oxazolidina-2-ona




330
WHO Drug Information Vol. 25, No. 3, 2011                                                Recommended INN: List 66


                                            C17H15FN6O3

                                                      O       O
                                                 H
                                            HO
                                                          N             F




                                                                                   N
                                                                            N
                                                                                       N CH3
                                                                                N N


 telotristatum
 telotristat                                4-(2-amino-6-{(1R -1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl) phenyl])-
                                            2,2,2-trifluoroethoxy}pyrimidin-4-yl)-L-phenylalanine

 télotristat                                4-(2-amino-6-{(1R)-1-[4-chloro-2-(3-méthyl-1H-pyrazol-1-yl)phényl]-
                                            2,2,2-trifluoroéthoxy}pryrimidin-4-yl)-L-phénylalanine

 telotristat                                4-(2-amino-6-{(1R -1-[4-cloro-2-(3-metil-1H-pirazol-1-il)fenil])-
                                            2,2,2-trifluoroetoxi}pirimidin-4-il)-L-fenilalanina

                                            C25H22ClF3N6O3

                                                                  NH2

                                                        H CF3 N      N

                                                              O                    H   NH2
                                                              N
                                            Cl            N                             CO2H
                                                                  CH3


 tregalizumabum #
 tregalizumab                               immunoglobulin G1-kappa, anti-[Homo sapiens CD4 (T cell surface
                                            antigen T4/Leu-3, p55)], humanized monoclonal antibody;
                                            gamma1 heavy chain (1-454) [humanized VH (Homo sapiens
                                            IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -Homo
                                            sapiens IGHG1*01 (125-454)], (227-218')-disulfide with kappa light
                                            chain (1'-218') [humanized V-KAPPA (Homo sapiens IGKV4-1*01
                                            (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                                            (112'-218')]; (233-233":236-236")-bisdisulfide dimer

 trégalizumab                               immunoglobuline G1-kappa, anti-[Homo sapiens CD4 (antigène de
                                            surface T4/Leu-3 de cellule T, p55)], anticorps monoclonal
                                            humanisé;
                                            chaîne lourde gamma1(1-454) [VH humanisé (Homo sapiens
                                            IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -Homo
                                            sapiens IGHG1*01 (125-454)], (227-218')-disulfure avec la chaîne
                                            légère kappa (1'-218') [V-KAPPA humanisé (Homo sapiens IGKV4-
                                            1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                                            (112'-218')]; dimère (233-233":236-236")-bisdisulfure

 tregalizumab                               inmunoglobulina G1-kappa, anti-[CD4 de Homo sapiens (antígeno
                                            de superficie T4/Leu-3 de célula T, p55)], anticuerpo monoclonal
                                            humanizado;
                                            cadena pesada gamma1(1-454) [VH humanizada (Homo sapiens
                                            IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -Homo
                                            sapiens IGHG1*01 (125-454)], (227-218')-disulfuro con la cadena
                                            ligera kappa (1'-218') [V-KAPPA humanizada (Homo sapiens IGKV4-
                                            1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                                            (112'-218')]; dimero (233-233":236-236")-bisdisulfuro


                                                                                                                331
Recommended INN: List 66                                       WHO Drug Information Vol. 25, No. 3, 2011


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EEQLVESGGG LVKPGGSLRL SCAASGFSFS                    DCRMYWLRQA       PGKGLEWIGV           50
                           ISVKSENYGA NYAESVRGRF TISRDDSKNT                    VYLQMNSLKT       EDTAVYYCSA          100
                           SYYRYDVGAW FAYWGQGTLV TVSSASTKGP                    SVFPLAPSSK       STSGGTAALG          150
                           CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                    LQSSGLYSLS       SVVTVPSSSL          200
                           GTQTYICNVN HKPSNTKVDK KVEPKSCDKT                    HTCPPCPAPE       LLGGPSVFLF          250
                           PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV                    KFNWYVDGVE       VHNAKTKPRE          300
                           EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV                    SNKALPAPIE       KTISKAKGQP          350
                           REPQVYTLPP SRDELTKNQV SLTCLVKGFY                    PSDIAVEWES       NGQPENNYKT          400
                           TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF                    SCSVMHEALH       NHYTQKSLSL          450
                           SPGK                                                                                     454

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSPDS LAVSLGERAT INCRASKSVS                    TSGYSYIYWY       QQKPGQPPKL 50
                           LIYLASILES GVPDRFSGSG SGTDFTLTIS                    SLQAEDVAVY       YCQHSRELPW 100
                           TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK                    SGTASVVCLL       NNFYPREAKV 150
                           QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                    STLTLSKADY       EKHKVYACEV 200
                           THQGLSSPVT KSFNRGEC                                                             218

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-98        151-207       268-328  374-432
                                     22''-98'' 151''-207'' 268''-328'' 374''-432''
                           Intra-L 23'-92'       138'-198'
                                    23'''-92''' 138'''-198'''
                           Inter-H-L 227-218' 227''-218'''
                           Inter-H-H 233-233'' 236-236''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           304, 304''


 turoctocogum alfa #
 turoctocog alfa           human coagulation factor VIII-(1-750)-(1638-2332)-peptide,
                           glycosylated

 turoctocog alfa           facteur VIII de coagulation humain-(1-750)-(1638-2332)-peptide
                           glycosylé

 turoctocog alfa           factor VIII de coagulación humano-(1-750)-(1638-2332)-péptido
                           glicosilado

                           C7480H11379N1999O2194S68 (peptide)

                           ATRRYYLGAV      ELSWDYMQSD       LGELPVDARF       PPRVPKSFPF       NTSVVYKKTL        50
                           FVEFTDHLFN      IAKPRPPWMG       LLGPTIQAEV       YDTVVITLKN       MASHPVSLHA       100
                           VGVSYWKASE      GAEYDDQTSQ       REKEDDKVFP       GGSHTYVWQV       LKENGPMASD       150
                           PLCLTYSYLS      HVDLVKDLNS       GLIGALLVCR       EGSLAKEKTQ       TLHKFILLFA       200
                           VFDEGKSWHS      ETKNSLMQDR       DAASARAWPK       MHTVNGYVNR       SLPGLIGCHR       250
                           KSVYWHVIGM      GTTPEVHSIF       LEGHTFLVRN       HRQASLEISP       ITFLTAQTLL       300
                           MDLGQFLLFC      HISSHQHDGM       EAYVKVDSCP       EEPQLRMKNN       EEAEDYDDDL       350
                           TDSEMDVVRF      DDDNSPSFIQ       IRSVAKKHPK       TWVHYIAAEE       EDWDYAPLVL       400
                           APDDRSYKSQ      YLNNGPQRIG       RKYKKVRFMA       YTDETFKTRE       AIQHESGILG       450
                           PLLYGEVGDT      LLIIFKNQAS       RPYNIYPHGI       TDVRPLYSRR       LPKGVKHLKD       500
                           FPILPGEIFK      YKWTVTVEDG       PTKSDPRCLT       RYYSSFVNME       RDLASGLIGP       550
                           LLICYKESVD      QRGNQIMSDK       RNVILFSVFD       ENRSWYLTEN       IQRFLPNPAG       600
                           VQLEDPEFQA      SNIMHSINGY       VFDSLQLSVC       LHEVAYWYIL       SIGAQTDFLS       650
                           VFFSGYTFKH      KMVYEDTLTL       FPFSGETVFM       SMENPGLWIL       GCHNSDFRNR       700
                           GMTALLKVSS      CDKNTGDYYE       DSYEDISAYL       LSKNNAIEPR       SFSQNSRHPS       750
                           QNPPVLKRHQ      REITRTTLQS       DQEEIDYDDT       ISVEMKKEDF       DIYDEDENQS       800
                           PRSFQKKTRH      YFIAAVERLW       DYGMSSSPHV       LRNRAQSGSV       PQFKKVVFQE       850
                           FTDGSFTQPL      YRGELNEHLG       LLGPYIRAEV       EDNIMVTFRN       QASRPYSFYS       900
                           SLISYEEDQR      QGAEPRKNFV       KPNETKTYFW       KVQHHMAPTK       DEFDCKAWAY       950
                           FSDVDLEKDV      HSGLIGPLLV       CHTNTLNPAH       GRQVTVQEFA       LFFTIFDETK       1000
                           SWYFTENMER      NCRAPCNIQM       EDPTFKENYR       FHAINGYIMD       TLPGLVMAQD       1050
                           QRIRWYLLSM      GSNENIHSIH       FSGHVFTVRK       KEEYKMALYN       LYPGVFETVE       1100
                           MLPSKAGIWR      VECLIGEHLH       AGMSTLFLVY       SNKCQTPLGM       ASGHIRDFQI       1150
                           TASGQYGQWA      PKLARLHYSG       SINAWSTKEP       FSWIKVDLLA       PMIIHGIKTQ       1200
                           GARQKFSSLY      ISQFIIMYSL       DGKKWQTYRG       NSTGTLMVFF       GNVDSSGIKH       1250
                           NIFNPPIIAR      YIRLHPTHYS       IRSTLRMELM       GCDLNSCSMP       LGMESKAISD       1300
                           AQITASSYFT      NMFATWSPSK       ARLHLQGRSN       AWRPQVNNPK       EWLQVDFQKT       1350
                           MKVTGVTTQG      VKSLLTSMYV       KEFLISSSQD       GHQWTLFFQN       GKVKVFQGNQ       1400
                           DSFTPVVNSL      DPPLLTRYLR       IHPQSWVHQI       ALRMEVLGCE       AQDLY            1445

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           153-179 248-329 528-554 630-711 945-971 1012-1016 1134-1282 1287-1439

                           Sulfated residues (Y) / Résidus sulfatés (Y) / Residuos sulfatados(Y)
                           Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-777 Tyr-793

                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-41 Asn-239 Asn-923 Asn-1231




332
WHO Drug Information Vol. 25, No. 3, 2011                                                             Recommended INN: List 66




 ublituximabum #
 ublituximab                                immunoglobulin G1-kappa, anti-[Homo sapiens MS4A1 (membrane-
                                            spanning 4-domains subfamily A member 1, B lymphocyte surface
                                            antigen B1, leukocyte surface antigen Leu-16, Bp35, CD20),
                                            chimeric monoclonal antibody;
                                            gamma1 heavy chain (1-448) [Mus musculus VH (IGHV1-12*01 -
                                            (IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01 (119-
                                            448)], (221-213')-disulfide with kappa light chain (1'-213') [Mus
                                            musculus V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -
                                            Homo sapiens IGKC*01 (107'-213')]; (227-227'':230-230'')-
                                            bisdisulfide dimer

 ublituximab                                immunoglobuline G1-kappa, anti-[Homo sapiens MS4A1 (membre 1
                                            de la sous-famille A avec 4 transmembrane regions, antigène de
                                            surface B1 des lymphocytes B, antigène de surface Leu-16 des
                                            leucocytes, Bp35, CD20), anticorps monoclonal chimérique;
                                            chaîne lourde gamma1 (1-448) [Mus musculus VH (IGHV1-12*01 -
                                            (IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01 (119-
                                            448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213')
                                            [Mus musculus V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106')
                                            -Homo sapiens IGKC*01 (107'-213')]; dimère (227-227'':230-230'')-
                                            bisdisulfure

 ublituximab                                inmunoglobulina G1-kappa, anti-[MS4A1 de Homo sapiens
                                            (miembro 1 de la subfamilia A con 4 regiones , transmembrana ,
                                            antígeno de superficie B1 de linfocitos B, antígeno de superficie Leu-
                                            16 de leucocitos, Bp35, CD20), anticuerpo monoclonal quimérico;
                                            cadena pesada gamma1 (1-448) [Mus musculus VH(IGHV1-12*01 -
                                            (IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01 (119-
                                            448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [Mus
                                            musculus V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -
                                            Homo sapiens IGKC*01 (107'-213')]; dímero (227-227'':230-230'')-
                                            bisdisulfuro


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QAYLQQSGAE LVRPGASVKM SCKASGYTFT                  SYNMHWVKQT       PRQGLEWIGG        50
                                            IYPGNGDTSY NQKFKGKATL TVGKSSSTAY                  MQLSSLTSED       SAVYFCARYD       100
                                            YNYAMDYWGQ GTSVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                            FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                            CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                            TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                            TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                            SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                            Light chain / Chaîne légère / Cadena ligera
                                            QIVLSQSPAI LSASPGEKVT MTCRASSSVS                  YMHWYQQKPG       SSPKPWIYAT 50
                                            SNLASGVPAR FSGSGSGTSY SFTISRVEAE                  DAATYYCQQW       TFNPPTFGGG 100
                                            TRLEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                                            NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                                            SSPVTKSFNR GEC                                                                213

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H    22-96        145-201          262-322     368-426
                                                     22''-96''     145''-201''     262''-322'' 368''-426''
                                            Intra-L    23'-87'       133'-193'
                                                       23'''-87'''   133'''-193'''
                                            Inter-H-L     221-213'       221''-213'''
                                            Inter-H-H      227-227''      230-230''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            298, 298''




                                                                                                                                         333
Recommended INN: List 66                                     WHO Drug Information Vol. 25, No. 3, 2011




 urelumabum #
 urelumab                  immunoglobulin G4-kappa, anti-[Homo sapiens TNFRSF9 (tumor
                           necrosis factor receptor superfamily member 9, 4-1BB, T cell antigen
                           ILA, CD137)], Homo sapiens monoclonal antibody;
                           gamma4 heavy chain (1-448) [Homo sapiens VH (IGHV4-34*01
                           (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 hinge
                           S10>P (229) (122-448)], (135-216')-disulfide with kappa light chain
                           (1'-216') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -
                           IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; (227-
                           227'':230-230'')-bisdisulfide dimer

 urélumab                  immunoglobuline G4-kappa, anti-[Homo sapiens TNFRSF9 (membre
                           9 de la superfamille des récepteurs du facteur de nécrose tumorale,
                           4-1BB, antigène ILA de lymphocyte T, CD137)], Homo sapiens
                           anticorps monoclonal;
                           chaîne lourde gamma4 (1-448) [Homo sapiens VH (IGHV4-34*01
                           (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 charnière
                           S10>P (229) (122-448)], (135-216')-disulfure avec la chaîne légère
                           kappa (1'-216') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -
                           IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dimère
                           (227-227'':230-230'')-bisdisulfure

 urelumab                  inmunoglobulina G4-kappa, anti-[TNFRSF9 de Homo sapiens
                           (miembro 9 de la superfamilia de receptores del factor de necrosis
                           tumoral, 4-1BB, antígeno ILA de linfocito T, CD137)], anticuerpo
                           monoclonal de Homo sapiens;
                           cadena pesada gamma4 (1-448) [Homo sapiens VH (IGHV4-34*01
                           (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 bisagra
                           S10>P (229) (122-448)], (135-216')-disulfuro con la cadena ligera
                           kappa (1'-216') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -
                           IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dímero
                           (227-227'':230-230'')-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQWGAG LLKPSETLSL TCAVYGGSFS                  GYYWSWIRQS       PEKGLEWIGE        50
                           INHGGYVTYN PSLESRVTIS VDTSKNQFSL                  KLSSVTAADT       AVYYCARDYG       100
                           PGNYDWYFDL WGRGTLVTVS SASTKGPSVF                  PLAPCSRSTS       ESTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTK       200
                           TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC                  PAPEFLGGPS       VFLFPPKPKD       250
                           TLMISRTPEV TCVVVDVSQE DPEVQFNWYV                  DGVEVHNAKT       KPREEQFNST       300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP                  SSIEKTISKA       KGQPREPQVY       350
                           TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                           SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH                  EALHNHYTQK       SLSLSLGK         448

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                           ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPPALTF 100
                           CGGTKVEIKR TVAAPSVFIF PPSDEQLKSG                  TASVVCLLNN       FYPREAKVQW 150
                           KVDNALQSGN SQESVTEQDS KDSTYSLSST                  LTLSKADYEK       HKVYACEVTH 200
                           QGLSSPVTKS FNRGEC                                                             216

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-95        148-204       262-322  368-426
                                     22''-95'' 148''-204'' 262''-322'' 368''-426''
                           Intra-L 23'-88'      136'-196'
                                    23'''-88''' 136'''-196'''
                           Inter-H-L 135-216' 135''-216'''
                           Inter-H-H 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           298, 298''




334
WHO Drug Information Vol. 25, No. 3, 2011                                                   Recommended INN: List 66


 usistapidum
 usistapide                                 methyl (2S)-2-phenyl-2-[4-(4-{4'-(trifluoromethyl)-[1,1'-biphenyl]-
                                            2-carboxamido}phenyl)piperidin-1-yl]acetate

 usistapide                                 (+)-(2S)-2-phényl-2-{4-[4-({[4'-(trifluorométhyl)-[1,1'-biphényl]-
                                            2-yl]carbonyl}amino)phényl]pipéridin-1-yl}acétate de méthyle

 usistapida                                 (2S)-2-fenil-2-[4-(4-{4'-(trifluorometil)-[1,1'-bifenil]-
                                            2-carboxamido}fenil)piperidin-1-il]acetato de metilo

                                            C34H31F3N2O3

                                                                                  O       CH3
                                               CF3                            H       O

                                                                            N

                                                     O

                                                         N
                                                         H




 vesencumabum #
 vesencumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens NRP1 (neuropilin 1,
                                            NRP, vascular endothelial cell growth factor 165 receptor, VEGF165
                                            receptor, VEGF165R, CD304) extracellular domain], Homo sapiens
                                            monoclonal antibody;
                                            gamma1 heavy chain (1-453) [Homo sapiens VH (IGHV3-23*04
                                            (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3
                                            D12>E (362), L14>M (364) (124-453)], (226-214')-disulfide with
                                            kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01
                                            (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (232-
                                            232'':235-235'')-bisdisulfide dimer

 vésencumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens NRP1 (neuropiline
                                            1, NRP, récepteur de l'isoforme 165 du facteur de croissance des
                                            cellules endothéliales vasculaires, récepteur du VEGF165,
                                            VEGF165R, CD304) domaine extracellulaire], Homo sapiens
                                            anticorps monoclonal;
                                            chaîne lourde gamma1 (1-453) [Homo sapiens VH (IGHV3-23*04
                                            (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3
                                            D12>E (362), L14>M (364) (124-453)], (226-214')-disulfure avec la
                                            chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-
                                            39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                                            dimère (232-232'':235-235'')-bisdisulfure

 vesencumab                                 inmunoglobulina G1-kappa, anti-[NRP1 de Homo sapiens
                                            (neuropilina 1, NRP, receptor de la isoforma 165 del factor de
                                            crecimiento de células endoteliales vasculares, receptor de
                                            VEGF165, VEGF165R, CD304) dominio extracelular], anticuerpo
                                            monoclonal de Homo sapiens;
                                            cadena pesada gamma1 (1-453) [VH de Homo sapiens (IGHV3-
                                            23*04 (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3
                                            D12>E (362), L14>M (364) (124-453)], (226-214')-disulfuro con la
                                            cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-
                                            39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                                            dímero (232-232'':235-235'')-bisdisulfuro




                                                                                                                  335
Recommended INN: List 66                                        WHO Drug Information Vol. 25, No. 3, 2011




                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  SYAMSWVRQA       PGKGLEWVSQ        50
                           ISPAGGYTNY ADSVKGRFTI SADTSKNTAY                  LQMNSLRAED       TAVYYCARGE       100
                           LPYYRMSKVM DVWGQGTLVT VSSASTKGPS                  VFPLAPSSKS       TSGGTAALGC       150
                           LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSSLG       200
                           TQTYICNVNH KPSNTKVDKK VEPKSCDKTH                  TCPPCPAPEL       LGGPSVFLFP       250
                           PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                  FNWYVDGVEV       HNAKTKPREE       300
                           QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                  NKALPAPIEK       TISKAKGQPR       350
                           EPQVYTLPPS REEMTKNQVS LTCLVKGFYP                  SDIAVEWESN       GQPENNYKTT       400
                           PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                  CSVMHEALHN       HYTQKSLSLS       450
                           PGK                                                                                 453

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQYFS                  SYLAWYQQKP       GKAPKLLIYG 50
                           ASSRASGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       YLGSPPTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        150-206       267-327  373-431
                                     22''-96'' 150''-206'' 267''-327'' 373''-431''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 226-214' 226''-214'''
                           Inter-H-H 232-232'' 235-235''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           303, 303''



 vidupiprantum
 vidupiprant               {4-[4-(tert-butylcarbamoyl)-2-(2-chloro-
                           4-cyclopropylbenzenesulfonamido)phenoxy]-5-chloro-
                           2-fluorophenyl}acetic acid

 vidupiprant               acide {4-[4-(tert-butylcarbamoyl)-2-(2-chloro-
                           4-cyclopropylbenzènesulfonamido)phénoxy]-5-chloro-
                           2-fluorophényl}acétique

 vidupiprant               ácido {4-[4-(terc-butilcarbamoil)-2-(2-cloro-
                           4-ciclopropilbencenosulfonamido)fenoxi]-5-cloro-2-fluorofenil}acético

                           C28H27Cl2FN2O6S

                                                                     Cl
                                                          O
                             H3C      H
                                      N                                        CO2H
                           H3C                             NH
                                   CH3    O                S       O F
                                                               O
                                                           Cl




 vosaroxinum
 vosaroxin                 7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-
                           1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

 vosaroxine                acide 7-[(3S,4S)-3-méthoxy-4-(méthylamino)pyrrolidin-1-yl]-4-oxo-
                           1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphtyridine-3-carboxylique

 vosaroxina                ácido 7-[(3S,4S)-4-(metilamino)-3-metoxipirrolidin-1-il]-4-oxo-
                           1-(1,3-tiazol-2-il)-1,4-dihidro-1,8-naftiridina-3-carboxílico




336
WHO Drug Information Vol. 25, No. 3, 2011                                                         Recommended INN: List 66


                                                    C18H19N5O4S

                                                                     CH3
                                                                HN
                                                            H                  N       S
                                                        H
                                                    H3CO             N     N       N


                                                                                           CO2H
                                                                                   O




                                     AMENDMENTS TO PREVIOUS LISTS
                            MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                                MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 51
Dénominations communes internationales proposées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)


p. 86   cantuzumabum mertansinum#
        cantuzumab mertansine               replace the description and the structure by the following ones
        cantuzumab mertansine               remplacer la description et la structure par les suivantes
        cantuzumab mertansina               sustitúyase la descripción y la estructura por las siguientes

                                            immunoglobulin G1-kappa, anti-[Homo sapiens MUC1 sialylated
                                            carbohydrate, tumour-associated (CA242, cancer antigen 242)], humanized
                                            monoclonal antibody conjugated to maytansinoid DM1;
                                            gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV7-4-1*02
                                            (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -
                                            Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfide with kappa light
                                            chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-28*01
                                            (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9]
                                            (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (228-228":231-231")-
                                            bisdisulfide dimer; conjugated, on an average of 4 lysyl, to maytansinoid
                                                    2'           2'
                                            DM1 [N -deacetyl-N -(3-mercapto-1-oxopropyl)-maytansine] via the
                                            reductible SPP linker [N-succinimidyl 4-(2-pyridyldithio)pentanoate]
                                            For the mertansine part, please refer to the document "INN for
                                            pharmaceutical substances: Names for radicals, groups and others"*

                                            immunoglobuline G1-kappa, anti-[Homo sapiens glycane sialylé de MUC1,
                                            associé à des tumeurs (CA242, antigène du cancer 242)], anticorps
                                            monoclonal humanisé conjugué au maytansinoïde DM1;
                                            chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens IGHV7-4-
                                            1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-
                                            119) -Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfure avec la
                                            chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-
                                            28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111))
                                            [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (228-
                                            228":231-231")-bisdisulfure; conjugué, sur 4 lysyl en moyenne, au
                                                                   2'            2'
                                            maytansinoïde DM1 [N -déacétyl-N -(3-mercapto-1-oxopropyl)-maytansine]
                                            via le linker SPP réductible [4-(2-pyridyldithio)pentanoate de
                                            N-succinimidyle]
                                            Pour la partie mertansine, veuillez vous référer au document "INN for
                                            pharmaceutical substances: Names for radicals, groups and others"*




                                                                                                                       337
Recommended INN: List 66                                                         WHO Drug Information Vol. 25, No. 3, 2011




                           inmunoglobulina G1-kappa, anti-[glicano sialilado de MUC1 de Homo sapiens,
                           asociado a tumores (CA242, antígeno del cáncer 242)], anticuerpo monoclonal
                           humanizado conjugado con el maitansinoide DM1;
                           cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens IGHV7-4-
                           1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-
                           119) -Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena
                           ligera kappa (1'-219') [V-KAPPA humanizada (Homo sapiens IGKV2-28*01
                           (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-
                           112') -Homo sapiens IGKC*01 (113'-219')]; dímero (228-228":231-231")-
                           bisdisulfuro; conjugado, por término medio, en 4 grupos lisil, con el
                                                   2           2
                           maitansinoide DM1 [N '-desacetil-N '-(3-mercapto-1-oxopropil)-maitansina]
                           mediante el espaciador SPP reducible [4-(2-piridilditio)pentanoato de
                           N-succinimidilo]
                           Para la mertansina, por favor, consulten el documento "INN for pharmaceutical
                           substances: Names for radicals, groups and others"*.


                              cantuzumab/ cantuzumab / cantuzumab
                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGETVKI SCKASDYTFT                      YYGMNWVKQA   PGQGLKWMGW        50
                           IDTTTGEPTY AQKFQGRIAF SLETSASTAY                      LQIKSLKSED   TATYFCARRG       100
                           PYNWYFDVWG QGTTVTVSSA STKGPSVFPL                      APSSKSTSGG   TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                      LYSLSSVVTV   PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                      CPAPELLGGP   SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                      VDGVEVHNAK   TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                      PAPIEKTISK   AKGQPREPQV       350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                      VEWESNGQPE   NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                      HEALHNHYTQ   KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSPLS VPVTPGEPVS ISCRSSKSLL                      HSNGNTYLYW   FLQRPGQSPQ 50
                           LLIYRMSNLV SGVPDRFSGS GSGTAFTLRI                      SRVEAEDVGV   YYCLQHLEYP 100
                           FTFGPGTKLE LKRTVAAPSV FIFPPSDEQL                      KSGTASVVCL   LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                      SSTLTLSKAD   YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96       146-202        263-323  369-427
                                    22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-93'      139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 222-219' 222''-219'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''
                                 mertansine / mertansine / mertansina

                                      O                            O    H CH3
                                                  S                              O
                            Ig    N                    S               N
                                  H
                                               CH3         H3C         CH3   O
                                                                                 CH3   Cl
                                                               O             H
                                                       H3C                       N          OCH3
                                                                       H
                                                           H       H
                                                                             O
                                                           O
                                                                       OH
                                                      O        N
                                                               H
                                                                   H OCH3            CH3
                                                                                              4

                                                     cantuzumab = Ig(NH2)4




338
WHO Drug Information Vol. 25, No. 3, 2011                                                 Recommended INN: List 66




Recommended International Non Proprietary Names (Rec. INN): List 65
Dénominations communes internationales proposées (DCI Rec.): Liste 65
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 65
(WHO Drug Information, Vol. 25, No. 1, 2011)


p. 84     samalizumabum #
          samalizumab                  replace the description by the following one
          samalizumab                  remplacer la description par la suivante
          samalizumab                  sustitúyase la descripción por la siguiente

                                       immunoglobulin G2/4-kappa, anti-[Homo sapiens CD200 (OX-2)], humanized
                                       monoclonal antibody;
                                       gamma2/4 heavy chain (1-442) [humanized VH (Homo sapiens IGHV1-69*01
                                       (73.50%) -(IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) -
                                       Homo sapiens IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2
                                       1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfide with kappa light
                                       chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01 (81.10%) -
                                       IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                       (219-219":220-220":223-223":226-226")-tetrakisdisulfide dimer

                                       immunoglobuline G2/4-kappa, anti-[Homo sapiens CD200 (OX-2)], anticorps
                                       monoclonal humanisé;
                                       chaîne lourde gamma2/4 (1-442) [VH humanisé (Homo sapiens IGHV1-69*01
                                       (73.50%) -(IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) -
                                       Homo sapiens IGHG2*01 CH1-charnière-CH2 1.6-1.1 (118-232)- IGHG4*01
                                       CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfure avec la
                                       chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-
                                       33*01 (81.10%) -IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -Homo sapiens
                                       IGKC*01 (108'-214')]; dimère (219-219":220-220":223-223":226-226")-
                                       tétrakisdisulfure

                                       inmunoglobulina G2/4-kappa, anti-[Homo sapiens CD200 (OX-2)], anticuerpo
                                       monoclonal humanizado;
                                       cadena pesada gamma2/4 (1-442) [humanizado VH (Homo sapiens IGHV1-
                                       69*01 (73.50%) - (IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-
                                       117) -Homo sapiens IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)- IGHG4*01
                                       CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfuro con la cadena
                                       ligera kappa (1'-214') [V-KAPPA humanizada(Homo sapiens IGKV1-33*01
                                       (81.10%) -IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                                       (108'-214')]; dímero (219-219":220-220":223-223":226-226")-tetrakisdisulfuro



p. 95     vorapaxarum
          vorapaxar                    replace the chemical name by the following

                                       ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3-fluorophenyl)pyridin-
                                       2-yl]ethen-1-yl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate




                                                                                                                  339
 Recommended INN: List 66                                                 WHO Drug Information Vol. 25, No. 3, 2011



 * "INN for pharmaceutical substances: Names for radicals, groups & others" document available at /
 document disponible à / documento disponible en :
 http://www.who.int/medicines/services/inn/publication/en/index.html

 # Electronic structure available on Mednet: http://mednet.who.int/
 # Structure électronique disponible sur Mednet: http://mednet.who.int/
 # Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 340
